Methods for the diagnosis and treatment of essential primary hypertension

Abstract

The present invention belongs to the field of molecular diagnosis of medical diseases and their treatment. More specifically, the present invention provides methods and means for detecting hypertension, more specifically essential primary hypertension, and even more specifically NOX5-dependent hypertension. The present invention also provides methods for treating hypertension, more specifically essential primary hypertension, and more specifically NOX5-dependent hypertension. The present invention also provides theragnostics combining therapy with diagnosis, more specifically, determining the level of NOX5 in a sample from a subject, and treating the subject with a NOX5 inhibitor or a compound that reduces the level of NOX5 if the NOX5 level exceeds a certain threshold. Furthermore, the present invention also provides theragnostics combining diagnosis with therapy, more specifically, determining the level of NOX5 (plasma) in a sample from a subject, and treating the subject with a NOX5 inhibitor or a compound that reverses the consequences of NOX5 activity if the determined NOX5 level exceeds a predetermined threshold. Finally, the present invention relates to animal models suitable for developing diagnostic methods and therapeutic treatments for NOX5-dependent hypertension.

Description

[Technical Field]

[0001] The present invention belongs to the field of molecular diagnosis of medical diseases and their treatment. More specifically, the present invention provides methods and means for detecting hypertension, more specifically essential primary hypertension, and even more specifically NOX5-dependent hypertension. The present invention also provides methods for treating hypertension, more specifically essential primary hypertension, and more specifically NOX5-dependent hypertension. The present invention also provides theragnostics combining therapy with diagnosis, more specifically, determining the level of NOX5 in a sample from a subject, and treating the subject with a NOX5 inhibitor or a compound that reduces the level of NOX5 if the NOX5 level exceeds a certain threshold. Furthermore, the present invention also provides theragnostics combining diagnosis with therapy, more specifically, determining the level of NOX5 (plasma) in a sample from a subject, and treating the subject with a NOX5 inhibitor or a compound that reverses the consequences of NOX5 activity if the determined NOX5 level exceeds a predetermined threshold. Finally, the present invention relates to animal models suitable for developing diagnostic methods and therapeutic treatments for NOX5-dependent hypertension. [Background technology]

[0002] Hypertension is of great medical relevance as a risk factor for myocardial infarction, stroke and other chronic conditions and death (Olsen MH, Angell SY, Asma S, Boutouyrie P, Burger D, Chirinos JA, et al. A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. Lancet. 2016;388(10060):2665-712. Epub 2016 / 09 / 28. doi: 10.1016 / S0140-6736(16)31134-5. PubMed PMID: 27671667). With the exception of 5% of patients with secondary hypertension (resulting from renal artery stenosis, adrenal adenoma, pheochromocytoma, and numerous signaling gene mutations affecting renal transporters (Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, Cifkova R, Dominiczak AF, et al. Hypertension. Nat Rev Dis Primers. 2018;4:18014. Epub 2018 / 03 / 23. doi: 10.1038 / nrdp.2018.14. PubMed PMID: 29565029; PubMed Central PMCID: PMCPMC6477925)), the cause of hypertension is unknown in the remaining 95% of cases. In these cases of so-called "essential primary hypertension," treatment should focus on symptomatic vasodilatory medications and lifestyle management.In resistant hypertension, even symptomatic antihypertensive therapy may be ineffective, yet the number needed to treat is high and many patients continue to experience adverse events such as stroke and myocardial infarction (Ogden LG, He J, Lydick E, Whelton PK. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension. 2000;35(2):539-43. Epub 2000 / 02 / 19. doi: 10.1161 / 01.hyp.35.2.539. PubMed PMID: 10679494).

[0003] One molecular mechanism of hypertension that has been proposed for decades is oxidative stress, i.e., the nonphysiological generation of reactive oxygen species (ROS), which interfere with vasodilation mediated by nitric oxide (NO), an endothelium-derived relaxing factor, in blood vessels (Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature. 1986;320(6061):454-6. Epub 1986 / 04 / 03. doi: 10.1038 / 320454a0. PubMed PMID: 3007998). However, the cellular source of ROS associated with hypertension has not yet been identified to substantiate this hypothesis or to exploit it for mechanism-based or even curative clinical therapies.

[0004] Recent genome-wide association studies (GWAS) searching for hypertension risk genes (Kraja AT, Cook JP, Warren HR, Surendran P, Liu C, Evangelou E, et al. New Blood Pressure-Associated Loci Identified in Meta-Analyses of 475 000 Individuals. Circ Cardiovasc Genet. 2017;10(5). Epub 2017 / 10 / 17. doi: 10.1161 / CIRCGENETICS.117.001778. PubMed PMID: 29030403; PubMed Central PMCID: PMCPMC5776077) have pointed to the only known enzyme family specialized in ROS formation: NADPH oxidases (NOXs), specifically the genes Nox4 and Nox5. This is consistent with preclinical studies, which have excluded other vascular NOX isoforms, namely NOX1 and NOX2, in eliciting hypertension in the absence of hypertensive drug infusion in animals (Yogi A, Mercure C, Touyz J, Callera GE, Montezano AC, Aranha AB, et al. Renal redox-sensitive signaling, but not blood pressure, is attenuated by Nox1 knockout in angiotensin II-dependent chronic hypertension. Hypertension. 2008;51(2):500-6. Epub 2008 / 01 / 16. doi: 10.1161 / HYPERTENSIONAHA.107.103192. PubMed PMID: 18195161, Murdoch CE, Alom-Ruiz SP, Wang M, Zhang M, Walker S, Yu B, et al.Role of endothelial Nox2 NADPH oxidase in angiotensin II-induced hypertension and vasomotor dysfunction. Basic Res Cardiol. 2011;106(4):527-38. Epub 2011 / 04 / 30. doi: 10.1007 / s00395-011-0179-7. PubMed PMID: 21528437; PubMed Central PMCID: PMCPMC3105229, Sag CM, Schnelle M, Zhang J, Murdoch CE, Kossmann S, Protti A, et al. Distinct Regulatory Effects of Myeloid Cell and Endothelial Cell NAPDH Oxidase 2 on Blood Pressure. Circulation. 2017;135(22):2163-77. Epub 2017 / 03 / 17. doi: 10.1161 / CIRCULATIONAHA.116.023877. PubMed PMID: 28298457; PubMed Central PMCID: PMCPMC5444427). Regarding NOX4, although this isoform is widely expressed, it appears to be unrelated to blood pressure or hypertension (Kleinschnitz C, Grund H, Wingler K, Armitage ME, Jones E, Mittal M, et al. Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS biology. 2010;8(9). Epub 2010 / 09 / 30. doi: 10.1371 / journal.pbio.1000479. PubMed PMID: 20877715), and is rather vasoprotective (Ray R, Murdoch CE, Wang M, Santos CX, Zhang M, Alom-Ruiz S, et al.Endothelial Nox4 NADPH oxidase enhances vasodilation and reduces blood pressure in vivo. Arterioscler Thromb Vasc Biol. 2011;31(6):1368-76. Epub 2011 / 03 / 19. doi: 10.1161 / ATVBAHA.110.219238. PubMed PMID: 21415386). Regarding NOX5, this enzyme is physiologically expressed in endothelial cells of human blood vessels and may be associated with diabetic nephropathy (Holterman CE, Thibodeau JF, Towaij C, Gutsol A, Montezano AC, Parks RJ, et al. Nephropathy and elevated BP in mice with podocyte-specific NADPH oxidase 5 expression. J Am Soc Nephrol. 2014;25(4):784-97. doi: 10.1681 / ASN.2013040371. PubMed PMID: 24262797; PubMed Central PMCID: PMCPMC3968494, Jha JC, Banal C, Okabe J, Gray SP, Hettige T, Chow BSM, et al. NADPH Oxidase Nox5 Accelerates Renal Injury in Diabetic Nephropathy. Diabetes. 2017;66(10):2691-703. Epub 2017 / 07 / 28. doi: 10.2337 / db16-1585. PubMed PMID: 28747378, Jha JC, Dai A, Holterman CE, Cooper ME, Touyz RM, Kennedy CR, et al.Endothelial or vascular smooth muscle cell-specific expression of human NOX5 worsens renal inflammation, fibrosis and albuminuria in the Akita mouse. Diabetologia. 2019;62(9):1712-26. Epub 2019 / 06 / 22. doi: 10.1007 / s00125-019-4924-z. PubMed PMID: 31222503). However, mice expressing human NOX5 in vascular smooth muscle cells are normotensive (Montezano AC, De Lucca Camargo L, Persson P, Rios FJ, Harvey AP, Anagnostopoulou A, et al. NADPH Oxidase 5 Is a Pro-Contractile Nox Isoform and a Point of Cross-Talk for Calcium and Redox Signaling—Implications in Vascular Function. J Am Heart Assoc. 2018;7(12). Epub 2018 / 06 / 17. doi: 10.1161 / JAHA.118.009388. PubMed PMID: 29907654; PubMed Central PMCID: PMCPMC6220544). Thus, the role of NOX5 in hypertension remains unclear.

[0005] Moving away from single targets, network medicine (Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet. 2011;12(1):56-68. Epub 2010 / 12 / 18. doi: 10.1038 / nrg2918. PubMed PMID: 21164525; PubMed Central PMCID: PMCPMC3140052) predicts that most diseases, especially complex ones, actually involve protein modules, i.e., subgraphs of interactomes, rather than single proteins (Alcaraz N, List M, Batra R, Vandin F, Ditzel HJ, Baumbach J. De novo pathway-based biomarker identification. Nucleic Acids Res. 2017;45(16):e151. Epub 2017 / 09 / 22. doi: 10.1093 / nar / gkx642. PubMed PMID: 28934488; PubMed Central PMCID: PMCPMC5766193, Batra R, Alcaraz N, Gitzhofer K, Pauling J, Ditzel HJ, Hellmuth M, et al. On the performance of de novo pathway enrichment. NPJ Syst Biol Appl. 2017;3:6. Epub 2017 / 06 / 27. doi: 10.1038 / s41540-017-0007-2. PubMed PMID: 28649433; PubMed Central PMCID: PMCPMC5445589, Menche J, Sharma A, Kitsak M, Ghiassian SD, Vidal M, Loscalzo J, et al. Disease networks.Uncovering disease-disease relationships through the incomplete interactome. Science. 2015;347(6224):1257601. Epub 2015 / 02 / 24. doi: 10.1126 / science.1257601. PubMed PMID: 25700523; PubMed Central PMCID: PMCPMC4435741). Therefore, we set out to re-examine the association of NOX with hypertension and NO-dependent vasodilation using three complementary and unbiased in silico approaches, validating any predictions in both mice and, where possible, human patient samples. [Prior art documents] [Non-patent literature]

[0006] [Non-Patent Document 1] Olsen MH, Angell SY, Asma S, Boutouyrie P, Burger D, Chirinos JA, et al. A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. Lancet. 2016;388(10060):2665-712. Epub 2016 / 09 / 28. doi: 10.1016 / S0140-6736(16)31134-5. PubMed PMID: 27671667 [Non-patent document 2] Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, Cifkova R, Dominiczak AF, et al. Hypertension. Nat Rev Dis Primers. 2018;4:18014. Epub 2018 / 03 / 23. doi: 10.1038 / nrdp.2018.14. PubMed PMID: 29565029; PubMed Central PMCID: PMCPMC6477925

Non-Patent Document 3

Non-Patent Document 4

Non-Patent Document 5

Non-Patent Document 6

Non-Patent Document 7

Non-Patent Document 8

Non-Patent Document 9

Non-licensed literature 10

Non-licensed Document 11

Non-licensed Document 12

Non-licensed Document 13

Non-Patent Document 14

Non-Patent Document 15

[0007] The present invention relates to a novel method for diagnosing essential arterial hypertension in a subject, in particular NOX5-dependent hypertension in a subject, in which the level of NADPH oxidase 5 (NOX5) is determined in a body fluid or tissue sample from the subject, and if the level of NOX5 is above a predetermined threshold level, it is concluded that the subject has essential arterial hypertension, in particular NOX5-dependent hypertension.

[0008] In certain embodiments, the predetermined threshold level is 160 pg per ml.

[0009] The present invention relates to a method for diagnosing NOX5-dependent hypertension in a subject by testing for the presence of a nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 5 (NOX5) concentration of at least 160 pg per ml in a plasma sample obtained from the subject suffering from essential arterial hypertension.

[0010] In an exemplary embodiment, the diagnostic method of the present invention comprises: (a) isolating endothelial microparticles from a plasma sample; (b) measuring NOX5 in the endothelial microparticles of step (a) using a protein detection assay to determine the concentration of NOX5 in the plasma sample as pg of NOX5 per ml of plasma sample; and the (human) subject is diagnosed as suffering from NOX5-dependent hypertension if the concentration of NOX5 determined in step (b) is at least 160 pg NOX5 per ml of said plasma sample.

[0011] The present invention further relates to a compound selected from sepiapterin, L-citrulline, L-arginine, tetrahydrobiopterin, folic acid and a NOX5 inhibitor, in particular the NOX5 inhibitor 5,12-dihydroquinoxalino(2,3-B)quinoxaline (ML090), for use in treating a subject with essential arterial hypertension, in particular NOX5-dependent hypertension.

[0012] The present invention further relates to a compound selected from sepiapterin, folic acid, L-citrulline, L-arginine and tetrahydrobiopterin for use in a method for treating a subject with essential arterial hypertension, wherein the subject with essential arterial hypertension has a NOX5 plasma concentration of at least 160 pg NOX5 per ml of plasma.

[0013] The present invention further relates to a compound selected from sepiapterin, folic acid, L-citrulline, L-arginine, and tetrahydrobiopterin for use in a method of treating a subject with treatment-resistant hypertension.

[0014] The present invention further relates to a compound selected from sepiapterin, folic acid, L-citrulline, L-arginine, and tetrahydrobiopterin for use in a method of treating a subject with NOX5-dependent hypertension.

[0015] In a further embodiment, the present invention relates to the use of aged NOX5 knock-in animal models for the discovery and development of therapeutic and diagnostic agents for use in NOX5 and uncoupled NOS dependent (essential arterial) hypertension.

[0016] The present invention also relates to the use of mice with a knock-in human Nox5 gene for the discovery and development of therapeutic agents for use in and methods for the detection of NOX5-dependent hypertension in a subject. [Brief explanation of the drawings]

[0017] [Figure 1A] ~ [Figure 1D] Identification and clinical validation of NOX5 as a direct neighbor of endothelial NO-cGMP signaling in hypertension. A. NOX isoforms (gray nodes) and NO-cGMP-related proteins (light gray nodes) were used as seed nodes to construct the NOX module using the first neighbor subnetwork pruned based on SPD (middle panel). The resulting NOX module was validated using two disease module identification methods: global modularity optimization (left panel) and accumulative local method (right panel). Both methods identified NOX5 as the closest link to NO-cGMP signaling, while NOX1-4 and all other known ROS sources were excluded (not shown). B. NOX5 levels were measured by ELISA in endothelial microparticles (MPs) isolated from plasma of normotensive (NT, normotensive) normoalbuminuric subjects and hypertensive (HT, hypertensive) normoalbuminuric and microalbuminuric patients. C. NOX5 levels were elevated in hypertensive patients with normoalbuminuria (n = 20) compared with normotensive subjects (n = 10). NOX5 levels were even higher in hypertensive patients with microalbuminuria (n = 20). Comparisons between groups were performed by one-way ANOVA followed by Tukey's multiple comparison test. D. Subgroup analysis of all hypertensive patients showed a bimodal distribution (p = 0.0007, two-tailed F test, adjusted coefficient of determination = 0.9973). All data are expressed as the mean ± SEM of n independent experiments; *P < 0.05, ***P < 0.001. [Figure 2A] ~ [Figure 2E]Preclinical validation of NOX5 in hypertension. A. Both young WT and NOX5 KI mice were normotensive, but only KI mice became hypertensive with aging. B and C. There were no significant differences in systolic (B) and diastolic (C) blood pressure between young WT (n = 19) and KI (n = 20) mice. D and E. Aged KI mice (n = 33) had higher systolic blood pressure (D) but similar diastolic blood pressure (E) compared with WT (n = 31). Telemetry data were analyzed by two-way repeated measures ANOVA followed by Sidak's multiple comparison test. All data are expressed as the mean ± SEM of n individual animals; **P < 0.01. [Figure 3A] ~ [Figure 3C]Endothelial NOX5 induces endothelial dysfunction and hypertension by uncoupling NOS. A. Femoral arteries from aged KI mice (n = 9) preconstricted with phenylephrine (Phe) were less responsive to acetylcholine (Ach)-induced relaxation compared with WT mice (n = 9). However, pretreatment with sepiapterin (100 μM) improved relaxation in KI mice (n = 4) and was not different from WT mice (n = 3). B. Saphenous arteries from aged KI mice (n = 9) preconstricted with Phe showed no difference in Ach-induced relaxation compared with WT mice (n = 8). Myograph data were analyzed by two-way ANOVA followed by Sidak's multiple comparison test. C. Schematic representation of NOX5-induced age-dependent hypertension. During aging, endothelial NOX5 is activated and interferes with normal NO-cGMP signaling, resulting in impaired vascular smooth muscle relaxation and elevated blood pressure. Abbreviations: EC, endothelial cell; ET-1, endothelin-1; H4Bip, tetrahydrobiopterin; NA, noradrenaline; NOS3, endothelial nitric oxide synthase; SMC, smooth muscle cell; sGC, soluble guanylate cyclase; SN, sympathetic nerve. All data are expressed as mean ± SEM of n individual animals; ***P < 0.001. [Figure 4] Plasma ADMA levels in healthy and hypertensive subjects. ADMA levels were significantly higher in hypertensive patients (n = 40) compared with healthy subjects (n = 10). Comparisons between the two groups were performed by unpaired two-tailed t-test. All data are expressed as mean ± SEM, **P < 0.01. [Figure 5A] ~ [Figure 5B]Mean arterial pressure (MAP) in young and aged WT and KI mice. A. There was no significant difference in MAP between young WT (n = 19) and KI (n = 20). B. Aged KI mice (n = 33) had a higher MAP compared to WT (n = 31). Telemetry data were analyzed by two-way repeated measures ANOVA followed by Sidak's multiple comparison test. All data are expressed as the mean ± SEM of n individual animals; **P < 0.01. [Figure 6A] ~ [Figure 6E] Body and organ weights in aged WT and KI mice. A–E. Body, heart, and kidney weights did not differ between WT (n = 24) and KI mice (n = 20), but the lung / body weight ratio was higher in KI mice. Comparisons between groups were performed by unpaired two-tailed t-test. All data are expressed as the mean ± SEM of n individual animals; *P < 0.05. [Figure 7A] ~ [Figure 7C] Arterial stiffness in aged WT and KI mice. A-C. The relationship between wall tension at relaxation and arterial lumen diameter was not different between KI mice (n = 9) and WT mice (n = 9) in the thoracic aorta (A), femoral artery (B), and saphenous artery (C). All data are expressed as the mean ± SEM of n individual animals. [Figure 8A] ~ [Figure 8J]Acetylcholine (Ach)-induced relaxation in arteries from aged WT and KI mice. A-C. Ach-induced relaxation was impaired in the femoral artery (A) of aged KI mice (n = 9) preconstricted with K+ compared with WT mice (n = 8-9), but not in the saphenous artery (B) or thoracic aorta (with or without indomethacin) (C). D-F. Ach-induced relaxation was impaired in the femoral artery (D) of aged KI mice (n = 9) preconstricted with endothelin-1 compared with WT mice (n = 8-9), but not in the saphenous artery (E) or thoracic aorta (F) with or without indomethacin. G. There was no difference in Ach-induced relaxation in the thoracic aorta (with or without indomethacin) preconstricted with phenylephrine between WT (n = 9) and KI mice (n = 9). H-J. ACh-induced relaxation in arteries contracted with endothelin-1 was reversed by 100 μM L-NAME in the femoral artery (H) and thoracic aorta (I), but not in the saphenous artery (J), in both aged KI mice (n = 8-9) and WT mice (n = 8-9). Myograph data were analyzed by two-way ANOVA followed by Sidak's multiple comparison test. All data are expressed as the mean ± SEM of n individual animals; *P < 0.05. [Figure 9] qPCR of NOX5 in the thoracic aorta (TAO), femoral artery (FA), and saphenous artery (SA) of aged KI mice. There were no differences in NOX5 gene expression among the three vessel types (n = 3, each with duplicates). Comparisons were performed by one-way ANOVA. All data are expressed as the mean ± SEM of n individual animals. [Figure 10A] ~ [Figure 10I]Contractile responses in arteries of aged WT and KI mice. There were no differences in the contractile responses to K, phenylephrine, or endothelin-1 between WT mice (n = 8-9) and KI mice (n = 9) in the femoral artery (A-C), saphenous artery (D-F), and thoracic aorta (with or without indomethacin) (G-I). Comparisons of the contractile responses to K between two groups were performed by two-tailed t-test. Other myograph data were analyzed by two-way ANOVA followed by Sidak's multiple comparison test. All data are expressed as the mean ± SEM of n individual animals. [Figure 11A] ~ [Figure 11D] Endothelium-dependent relaxation in arteries of aged WT and KI mice. A–C. There was no difference in relaxation induced by the NO donor PAPANO (0.01–10 μM) in the femoral artery (A), saphenous artery (B), and thoracic aorta (with or without indomethacin) (C) between WT mice (n = 8–9) and KI mice (n = 9). D. There was no difference in relaxation induced by the apo-sGC activator Bay60-2770 (0.01–10 μM) in the femoral artery between WT mice (n = 4) and KI mice (n = 4). Myograph data were analyzed by two-way ANOVA followed by Sidak's multiple comparison test. All data are expressed as the mean ± SEM of n individual animals. [Figure 12A] ~ [Figure 12B] Acetylcholine (Ach)-induced relaxation in the femoral artery of aged KI mice treated with antioxidants. In femoral artery segments (n = 3–6) contracted with 10 μM phenylephrine, the relaxation effect of Ach (10 μM) was not reversed by either 10 μM N-acetylcysteine ​​(NAC) (A) or 100 μM tempol (B). Comparisons between groups were performed by unpaired two-tailed t-test. All data are expressed as the mean ± SEM of n individual animals. [Figure 13A] ~ [Figure 13N]Echocardiography in aged WT and KI mice. There were no differences in all parameters (A–N) between WT (n = 28) and KI mice (n = 29). Comparisons between groups were performed by unpaired two-tailed t-test. All data are expressed as the mean ± SEM of n individual animals. [Figure 14A] ~ [Figure 14C] Arterial diameters in aged WT and KI mice. There were no differences in the diameters of the thoracic aorta (A), femoral artery (B), and saphenous artery (C) with or without indomethacin between WT (n = 9) and KI mice (n = 9). Comparisons between groups were performed by unpaired two-tailed t-test. All data are expressed as the mean ± SEM of n individual animals. DETAILED DESCRIPTION OF THE INVENTION

[0018] To explore possible links between NOX isoforms and hypertension and NO-dependent vasodilation, we constructed pruned molecular subnetworks from NOX family members as seed nodes and first-neighbor nitric oxide-cyclic GMP-related proteins in experimentally validated interactomes obtained from the IID (Kotlyar M, Pastrello C, Malik Z, Jurisica I. IID 2018 update: context-specific physical protein-protein interactions in human, model organisms and domesticated species. Nucleic Acids Res. 2019;47(D1):D581-D9. Epub 2018 / 11 / 09. doi: 10.1093 / nar / gky1037. PubMed PMID: 30407591; PubMed Central PMCID: PMCPMC6323934) interactome database. These included NOX1, NOX3, NOX4, NOX5, NOS1, NOS3, GUCYA1, GUCYA2, GUCYB1, PDE5A, PDE9A, and PRKG1, but not NOX2 or NOS2.

[0019] The resulting subnetwork was further pruned according to subnetwork-participation-degree (SPD) to correct for hub nodes (i.e., proteins that arose primarily due to a high number of interactions in the overall network). This resulted in a disease module consisting of several connected components, which revealed that all NOX isoforms except NOX5 were excluded as close neighbors of endothelial NO cyclic GMP signaling. NOX5 was the same component connected to genes encoding the NO receptors GUCYA1, GUCYA2, and GUCYB1, as well as endothelial NOS (NOS3) (Figure 1A). According to IID, this connection is based on physical interactions suggested by high-throughput affinity chromatography (Huttlin EL, Bruckner RJ, Paulo JA, Cannon JR, Ting L, Baltier K, et al. Architecture of the human interactome defines protein communities and disease networks. Nature. 2017;545(7655):505-9. Epub 2017 / 05 / 18. doi: 10.1038 / nature22366. PubMed PMID: 28514442; PubMed Central PMCID: PMCPMC5531611).

[0020] To further confirm our in silico discovery of the NOX disease module, we employed two additional computational network module identification methods: global modularity optimization and agglomerative local search, both of which were top performers in the recent module identification DREAM challenge (Choobdar S, Ahsen ME, Crawford J, Tomasoni M, Fang T, Lamparter D, et al. Assessment of network module identification across complex diseases. Nat Methods. 2019;16(9):843-52. Epub 2019 / 09 / 01. doi: 10.1038 / s41592-019-0509-5. PubMed PMID: 31471613; PubMed Central PMCID: PMCPMC6719725). Briefly, the global modularity optimization approach combines multiple module detection algorithms to avoid suboptimal partitioning resulting from individual algorithms (Arenas A, Fernandez A, Gomez S. Analysis of the structure of complex networks at different resolution levels. New Journal of Physics. 2008;10(5):053039. doi: 10.1088 / 1367-2630 / 10 / 5 / 053039). The agglomerative local method uses the SPICi algorithm (Jiang P, Singh M. SPICi: a fast clustering algorithm for large biological networks. Bioinformatics. 2010;26(8):1105-11. Epub 2010 / 02 / 27. doi: 10.1093 / bioinformatics / btq078. PubMed PMID: 20185405; PubMed Central PMCID: PMCPMC2853685) to optimize the local density of modules around seed nodes.All three in silico methods led us to the same conclusion: all NOX genes except NOX5 were excluded as direct neighbors of endothelial nitric oxide cyclic GMP signaling ( Fig. 1A ).

[0021] To test this causative endothelial NOX5 hypothesis for human hypertension, we investigated the effects of NOX5 on the endothelial function of essential primary hypertension and hypertension at 30 mL / min / 1.73 m 2Consecutive outpatients with a baseline estimated glomerular filtration rate (eGFR) of ≥ 10 were enrolled. The study subjects were divided into three groups: healthy controls (n = 10), hypertensive patients with normoalbuminuria (n = 20), and hypertensive patients with moderately increased albuminuria (previously called microalbuminuria) (n = 20). Patient baseline characteristics are listed in Table 1. To measure NOX5 protein levels, circulating endothelial microparticles—membrane vesicles released from endothelial cells upon cell activation or death that deliver endothelial proteins (Dignat-George F, Boulanger CM. The many faces of endothelial microparticles. Arterioscler Thromb Vasc Biol. 2011;31(1):27-33. Epub 2010 / 12 / 17. doi: 10.1161 / ATVBAHA.110.218123. PubMed PMID: 21160065)—were isolated from participants' plasma (Figure 1B). We observed higher NOX5 protein levels in endothelial microparticles from hypertensive subjects compared with normotensive subjects, and within hypertensive subjects, patients with microalbuminuria showed even higher NOX5 protein levels (Figure 1C). These data suggest that NOX5 levels are associated with hypertension and correlate with disease severity. Hypertension is a fairly umbrella term that can encompass different molecular mechanisms that all lead to a similar phenotype: elevated blood pressure.NOX5-dependent hypertension may be such an endotype, but it applies to only a subset of patients. (Aguirre-Plans J, Pinero J, Menche J, Sanz F, Furlong LI, Schmidt H, et al. Proximal Pathway Enrichment Analysis for Targeting Comorbid Diseases via Network Endopharmacology. Pharmaceuticals (Basel). 2018;11(3). Epub 2018 / 06 / 23. doi: 10.3390 / ph11030061. PubMed PMID: 29932108; PubMed Central PMCID: PMCPMC6160959, Mazein A, Ostaszewski M, Kuperstein I, Watterson S, Le Novere N, Lefaudeux D, et al. Systems medicine disease maps: community-driven comprehensive representation of disease mechanisms. NPJ Syst Biol Appl. 2018;4:21.) Epub 2018 / 06 / 07. doi: 10.1038 / s41540-018-0059-y. PubMed PMID: 29872544; PubMed Central PMCID: PMCPMC5984630; Burns NS, Miller PW. Learning What We Didn't Know - The SPRINT Data Analysis Challenge. N Engl J Med. 2017;376(23):2205-7. Epub 2017 / 04 / 27. doi: 10.1056 / NEJMp1705323. PubMed PMID: 28445656). Therefore, we performed a subgroup analysis of all hypertensive patients and indeed found that NOX5 levels showed a bimodal distribution (Figure 1D).Based on this, approximately one in four hypertensive patients corresponds to the high NOX5 mechanotype, which, through PPI interactions, is thought to lead to dysfunctional NO-cGMP signaling. Furthermore, we determined plasma ADMA levels, a biomarker of NOS uncoupling and endothelial dysfunction (Förstermann U, Münzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation. 2006;113(13):1708-14. Epub 2006 / 04 / 06. doi: 10.1161 / CIRCULATIONAHA.105.602532. PubMed PMID: 16585403). We found that ADMA levels were significantly increased in hypertensive patients compared with healthy subjects (Figure 4), which is in accordance with previous findings (Perticone F, Sciacqua A, Maio R, Perticone M, Maas R, Boger RH, et al. Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential primary hypertension. J Am Coll Cardiol. 2005;46(3):518-23. Epub 2005 / 08 / 02. doi: 10.1016 / j.jacc.2005.04.040. PubMed PMID: 16053968, Sonmez A, Celebi G, Erdem G, Tapan S, Genc H, Tasci I, et al. Plasma apelin and ADMA Levels in patients with essential primary hypertension. Clin Exp Hypertens. 2010;32(3):179-83. Epub 2010 / 05 / 28. doi: 10.3109 / 10641960903254505. PubMed PMID: 20504125).

[0022] [Table 1] JPEG0007808049000002.jpg78155

[0023] In Table 1, triglycerides are expressed in mg / dL, blood glucose levels are in mg / dL, uric acid is in mg / dL, and adiponectin is in mg / dL.

[0024] We have investigated the possible role of NOX5 in endothelial NO-cGMP signaling dysfunction and hypertension in mice. However, mice lack the Nox5 gene. The present invention also relates to the use of mice with a knock-in human Nox5 gene to discover and develop therapeutic agents and detection methods for use in NOX5-dependent hypertension in subjects. We therefore analyzed a knock-in mouse model (Casas AI, Kleikers PW, Geuss E, Langhauser F, Adler T, Busch DH, et al. Calcium-dependent blood-brain barrier breakdown by NOX5 limits postreperfusion benefit in stroke. J Clin Invest. 2019;130:1772-8. Epub 2019 / 03 / 19. doi: 10.1172 / JCI124283. PubMed PMID: 30882367; PubMed Central PMCID: PMCPMC6436900) expressing human Nox5 in a physiological endothelial location (Figure 2A). However, in young (9–15 weeks old) NOX5 KI mice (n = 19–20) of both sexes, systolic blood pressure, diastolic blood pressure, and mean arterial pressure (MAP) were not different from age- and sex-matched wild-type (WT) mice (Figures 2B, 2C, and 5A). However, with aging (68–87 weeks), systolic blood pressure and MAP were significantly elevated throughout the day in KI mice (n = 33) compared with age- and sex-matched WT mice (n = 31) (Figures 2D and 5B). Diastolic blood pressure remained unchanged (Figure 2E), as heart weight-to-body weight ratios (Figure 6A) indicated the absence of cardiac hypertrophy in KI mice, consistent with the late (age-dependent) onset of hypertension. Furthermore, cardiac hypertrophy does not necessarily coexist with hypertension.Other hypertensive animal models, such as eNOS knockout (KO) mice, do not have cardiac hypertrophy (Bubikat A, De Windt LJ, Zetsche B, Fabritz L, Sickler H, Eckardt D, et al. Local atrial natriuretic peptide signaling prevents hypertensive cardiac hypertrophy in endothelial nitric-oxide synthase-deficient mice. J Biol Chem. 2005;280(22):21594-9. Epub 2005 / 03 / 29. doi: 10.1074 / jbc.M501103200. PubMed PMID: 15793309, Godecke A, Decking UK, Ding Z, Hirchenhain J, Bidmon HJ, Godecke S, et al. Coronary hemodynamics in endothelial NO synthase knockout mice. Circ Res. 1998;82(2):186-94. Epub 1998 / 02 / 19. doi: 10.1161 / 01.res.82.2.186. PubMed PMID: 9468189).This is consistent with the clinical observation that not all hypertensive patients (subgroups) have cardiac hypertrophy (Devereux RB, Pickering TG, Alderman MH, Chien S, Borer JS, Laragh JH. Left ventricular hypertrophy in hypertension. Prevalence and relationship to pathophysiologic variables. Hypertension. 1987;9(2 Pt 2):1153-60. Epub 1987 / 02 / 01. doi: 10.1161 / 01.hyp.9.2_pt_2.ii53. PubMed PMID: 2879790, Park JB, Schiffrin EL. Small artery remodeling is the most prevalent (earliest?) form of target organ damage in mild essential primary hypertension. J Hypertens. 2001;19(5):921-30. Epub 2001 / 06 / 08). doi: 10.1097 / 00004872-200105000-00013. PubMed PMID: 11393676, Cuspidi C, Sala C, Negri F, Mancia G, Morganti A, Italian Society of H. Prevalence of left-ventricular hypertrophy in hypertension: an updated review of echocardiographic studies. J Hum Hypertens. 2012;26(6):343-9. Epub 2011 / 11 / 25. doi: 10.1038 / jhh.2011.104. PubMed PMID: 22113443). Notably, there were no differences in blood pressure between male and female mice within the groups.

[0025] Taken together, our observations indicate that endothelial NOX5 expression leads to a selective increase in systolic arterial blood pressure during aging in mice. Having established the potential of NOX5 to induce a hypertensive phenotype, we proceeded to verify the mechanistic link with vascular NO-cGMP signaling suggested by our in silico network analysis.

[0026] We analyzed structural smooth muscle and endothelial vasomotor properties in the thoracic aorta, femoral artery, and saphenous artery isolated from aged knock-in (KI) and wild-type (WT) mice (n = 9) of both sexes. Collectively, these vessels encompass the full range of large elastic conduit arteries, muscular conduit arteries, and small resistance-bearing muscular arteries, respectively. There was no difference in the relationship between relaxed wall tension and arterial luminal diameter in the thoracic aorta, femoral artery, and saphenous artery of aged animals between KI and WT mice (Figure 7A-C). Therefore, it is unlikely that the blood pressure phenotype of KI mice is due to stiffening or inward tissue repair of conduit or resistance arteries. This is in line with previous studies showing that arterial structural stiffening is not common in rodent models of essential hypertension (Bezie Y, Lamaziere JM, Laurent S, Challande P, Cunha RS, Bonnet J, et al. Fibronectin expression and aortic wall elastic modulus in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol. 1998;18(7):1027-34. Epub 1998 / 07 / 22. doi: 10.1161 / 01.atv.18.7.1027. PubMed PMID: 9672062, Hayoz D, Rutschmann B, Perret F, Niederberger M, Tardy Y, Mooser V, et al. Conduit artery compliance and distensibility are not necessarily reduced in hypertension. Hypertension). 1992;20(1):1-6. Epub 1992 / 07 / 01. doi: 10.1161 / 01.hyp.20.1.1. PubMed PMID: 1618544, Lacolley P, Ghodsi N, Glazer E, Challande P, Brissac AM, Safar ME, et al.Influence of graded changes in vasomotor tone on the carotid arterial mechanics in live spontaneously hypertensive rats. Br J Pharmacol. 1995;115(7):1235-44. Epub 1995 / 08 / 01. doi: 10.1111 / j.1476-5381.1995.tb15031.x. PubMed PMID: 7582551; PubMed Central PMCID: PMCPMC1908801, Intengan HD, Schiffrin EL. Structure and mechanical properties of resistance arteries in hypertension: role of adhesion molecules and extracellular matrix determinants. Hypertension. 2000;36(3):312-8. Epub 2000 / 09 / 16. doi: 10.1161 / 01.hyp.36.3.312. PubMed PMID: 10988257) and clinical data, particularly from elderly hypertensive patients, are consistent with this finding (Bussy C, Boutouyrie P, Lacolley P, Challande P, Laurent S. Intrinsic stiffness of the carotid arterial wall material in essential hypertensives. Hypertension. 2000;35(5):1049-54. Epub 2000 / 05 / 20. doi: 10.1161 / 01.hyp.35.5.1049. PubMed PMID: 10818063, Laurent S, Girerd X, Mourad JJ, Lacolley P, Beck L, Boutouyrie P, et al.Elastic modulus of the radial artery wall material is not increased in patients with essential primary hypertension. Arterioscler Thromb. 1994;14(7):1223-31. Epub 1994 / 07 / 01. doi: 10.1161 / 01.atv.14.7.1223. PubMed PMID: 8018679, Laurent S, Hayoz D, Trazzi S, Boutouyrie P, Waeber B, Omboni S, et al. Isobaric compliance of the radial artery is increased in patients with essential primary hypertension. J Hypertens. 1993;11(1):89-98. Epub 1993 / 01 / 01. doi: 10.1097 / 00004872-199301000-00013. PubMed PMID: 8382244, Laurent S. Arterial wall hypertrophy and stiffness in essential hypertensive patients. Hypertension. 1995;26(2):355-62. Epub 1995 / 08 / 01. doi: 10.1161 / 01.hyp.26.2.355. PubMed PMID: 7635546). .

[0027] To verify the effect of endothelial NOX5 on endothelium-dependent NO-cGMP-mediated relaxation, arterial segments were depolarized (K +), α1-adrenergic activation (phenylephrine), or endothelin-1, followed by vasorelaxation induction with acetylcholine (Ach), a classical endothelium-derived relaxing factor stimulator (Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288(5789):373-6. Epub 1980 / 11 / 27. doi: 10.1038 / 288373a0. PubMed PMID: 6253831). In the femoral artery, K +Regardless of whether the arteries were preconstricted with phenylephrine or endothelin-1, the amplitude of the ACh-induced relaxation response was significantly smaller in KI mice than in WT mice (Figs. 3A, 8A, and 8D). Conversely, in the saphenous artery (Figs. 3B, 8B, and 8E) and thoracic aorta (Figs. 8C, 8F, and 8G), the ACh-induced relaxation response was not different between KI and WT mice.Comparing our study with previous studies, ACh-induced relaxation of saphenous arteries in both mouse groups appeared to be attenuated (Chennupati R, Lamers WH, Koehler SE, De Mey JG. Endothelium-dependent hyperpolarization-related relaxations diminish with age in murine saphenous arteries of both sexes. Br J Pharmacol. 2013;169(7):1486-99. Epub 2013 / 03 / 16. doi: 10.1111 / bph.12175. PubMed PMID: 23488619; PubMed Central PMCID: PMCPMC3724106, Chennupati R, Meens MJ, Marion V, Janssen BJ, Lamers WH, De Mey JG, et al. Endothelial arginine resynthesis contributes to the maintenance of vasomotor function in male diabetic mice. PLoS One. 2014;9(7):e102264. Epub 2014 / 07 / 18. doi: 10.1371 / journal.pone.0102264. PubMed PMID: 25033204; PubMed Central PMCID: PMCPMC4102520, Chennupati R, Meens MJ, Janssen BJ, van Dijk P, Hakvoort TBM, Lamers WH, et al. Deletion of endothelial arginase 1 does not improve vasomotor function in diabetic mice. Physiol Rep. 2018;6(11):e13717. Epub 2018 / 06 / 12. doi: 10.14814 / phy2.13717. PubMed PMID: 29890043; PubMed Central PMCID: PMCPMC5995309).There are two possible explanations for this discrepancy. First, we used very old mice, whereas other studies used young mice (Chennupati R, Lamers WH, Koehler SE, De Mey JG. Endothelium-dependent hyperpolarization-related relaxations diminish with age in murine saphenous arteries of both sexes. Br J Pharmacol. 2013;169(7):1486-99. Epub 2013 / 03 / 16. doi: 10.1111 / bph.12175. PubMed PMID: 23488619; PubMed Central PMCID: PMCPMC3724106, Chennupati R, Meens MJ, Marion V, Janssen BJ, Lamers WH, De Mey JG, et al. Endothelial arginine resynthesis contributes to the maintenance of vasomotor function in male diabetic mice. PLoS One. 2014;9(7):e102264. Epub 2014 / 07 / 18. doi: 10.1371 / journal.pone.0102264. PubMed PMID: 25033204; PubMed Central PMCID: PMCPMC4102520, Chennupati R, Meens MJ, Janssen BJ, van Dijk P, Hakvoort TBM, Lamers WH, et al. Deletion of endothelial arginase 1 does not improve vasomotor function in diabetic mice. Physiol Rep. 2018;6(11):e13717. Epub 2018 / 06 / 12. doi: 10.14814 / phy2.13717. PubMed PMID: 29890043; PubMed Central PMCID: PMCPMC5995309).Second, although we used mice with a mixed genetic background (80% 129 / Sv and 20% C57BI6), previous data have shown that endothelial-dependent relaxation is similar in 129 / Sv and C57BI6 mice (Ryan MJ, Didion SP, Davis DR, Faraci FM, Sigmund CD. Endothelial dysfunction and blood pressure variability in selected inbred mouse strains. Arterioscler Thromb Vasc Biol. 2002;22(1):42-8. Epub 2002 / 01 / 15. doi: 10.1161 / hq0102.101098. PubMed PMID: 11788459).

[0028] In segments of the thoracic aorta and femoral artery contracted with 256 nM endothelin-1, the relaxant effect of ACh was reversed by 100 μM L-NAME (a pharmacological inhibitor of NO synthase), with no significant difference between specimens from KI and WT mice (Fig. 8H and 8I). In the saphenous artery of both species, L-NAME did not alter the relaxant effect of ACh (Fig. 8J). This is consistent with our previous findings that ACh-induced relaxation is mediated by endothelium-dependent hyperpolarization but not NO in these resistance-sized arteries (Chennupati R, Lamers WH, Koehler SE, De Mey JG. Endothelium-dependent hyperpolarization-related relaxations diminish with age in murine saphenous arteries of both sexes. Br J Pharmacol. 2013;169(7):1486-99. Epub 2013 / 03 / 16. doi: 10.1111 / bph.12175. PubMed PMID: 23488619; PubMed Central PMCID: PMCPMC3724106, Chennupati R, Meens MJ, Marion V, Janssen BJ, Lamers WH, De Mey JG, et al. Endothelial arginine resynthesis contributes to the maintenance of vasomotor function in male diabetic mice. PLoS One. 2014;9(7):e102264. Epub 2014 / 07 / 18. doi: 10.1371 / journal.pone.0102264. PubMed PMID: 25033204; PubMed Central PMCID: PMCPMC4102520, Chennupati R, Meens MJ, Janssen BJ, van Dijk P, Hakvoort TBM, Lamers WH, et al.Deletion of endothelial arginase 1 does not improve vasomotor function in diabetic mice. Physiol Rep. 2018;6(11):e13717. Epub 2018 / 06 / 12. doi: 10.14814 / phy2.13717. PubMed PMID: 29890043; PubMed Central PMCID: PMCPMC5995309).

[0029] To investigate whether this caliber-specific effect on vasomotor function was due to differential expression of NOX5 throughout the systemic arterial tree, we measured NOX5 gene expression by quantitative PCR. However, there was no difference in NOX5 gene expression among the thoracic aorta, femoral artery, and saphenous artery of NOX5 KI mice (Fig. 9). These data suggest an age-dependent dysfunction of endothelial NO-cGMP signaling due to NOX5, and suggest that this effect is not uniformly distributed throughout the systemic arterial tree.

[0030] Next, we examined whether chronic changes in the underlying arterial smooth muscle layer might have contributed to the blood pressure and vasomotor phenotype observed in aged NOX5 KI mice. + The contractile responses to agonist-induced vasoconstriction and the sensitivity and maximal responsiveness to phenylephrine and endothelin-1 were similar between KI and WT mice in all arterial segments (Fig. 10A-I). Furthermore, the blunting of agonist-induced contractile responses by indomethacin was similar in the thoracic aorta of KI and WT mice (Fig. 10G-I).

[0031] To examine which components of NO-cGMP signaling were most likely affected, we investigated the effects of endothelial NO synthase (Gebhart V, Reiss K, Kollau A, Mayer B, Gorren ACF. Site and mechanism of uncoupling of nitric-oxide synthase: Uncoupling by monomerization and other misconceptions. Nitric Oxide. 2019;89:14-21. Epub 2019 / 04 / 26. doi: 10.1016 / j.niox.2019.04.007. PubMed PMID: 31022534) or NO receptor-soluble guanylyl cyclase (Mendes-Silverio CB, Leiria LO, Morganti RP, Anhe GF, Marcondes S, Monica FZ, et al. Activation of heme-oxidized soluble guanylyl cyclase, which produces oxidized or heme-unbound apo-sGC. cyclase with BAY 60-2770 in human platelets lead to overstimulation of the cyclic GMP signaling pathway. PLoS One. 2012;7(11):e47223. Epub 2012 / 11 / 13. doi: 10.1371 / journal.pone.0047223. PubMed PMID: 23144808; PubMed Central PMCID: PMCPMC3493568, Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, H SA, Meurer S, et al. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest. 2006;116(9):2552-61. Epub 2006 / 09 / 07. doi: 10.1172 / JCI28371.We investigated the uncoupling effect of α-glucan (PubMed PMID: 16955146; PubMed Central PMCID: PMCPMC1555649) on oxidative damage. To investigate sGC / apo-sGC, we used the NO donor compound and sGC stimulator PAPA / NO (0.01-10 μM) (Hrabie JA, Klose JR, Wink DA, Keefer LK. New nitric oxide-releasing zwitterions derived from polyamines. The Journal of Organic Chemistry. 1993;58(6):1472-6. doi: 10.1021 / jo00058a030) and the apo-sGC activator BAY 60-2770 (0.01-10 μM) (Mendes-Silverio CB, Leiria LO, Morganti RP, Anhe GF, Marcondes S, Monica FZ, et al. Activation of heme-oxidized soluble guanylyl cyclase with BAY 60-2770 in human platelets lead to overstimulation of the cyclic GMP signaling. We analyzed the relaxation responses to PAPA / NO (Figures 13A-C) and BAY 60-2770 (Figure 11D) in aged NOX5 KI mice. These observations suggested that sGCs are not dysfunctional in aged NOX5 KI mice.

[0032] Endothelial NOS uncoupling is thought to be a key factor in endothelial dysfunction, characterized by decreased NOX formation and increased superoxide production, and occurs primarily when ROS oxidize the NOS cofactor tetrahydrobiopterin (H4Bip) (Kietadisorn R, Juni RP, Moens AL. Tackling endothelial dysfunction by modulating NOS uncoupling: new insights into its pathogenesis and therapeutic possibilities. Am J Physiol Endocrinol Metab. 2012;302(5):E481-95. Epub 2011 / 12 / 15. doi: 10.1152 / ajpendo.00540.2011. PubMed PMID: 22167522). When we incubated femoral arteries from aged NOX5 KI mice preconstricted with phenylephrine and the H4Bip precursor sepiapterin (100 μM), ACh-induced relaxation was greatly improved and indistinguishable from that in WT mice (Figure 3A). Furthermore, femoral arteries from aged NOX5 KI mice exhibited higher superoxide generation (as indicated by DHE staining) than WT mice, and this increase was blocked by pretreatment with the NOS inhibitor L-NAME.

[0033] We also tested whether the impaired Ach-induced relaxation in the femoral arteries of NOX5 KI mice could be reversed by adding antioxidants to the bath medium. However, neither 10 μM N-acetylcysteine ​​nor 100 μM tempol was effective (Figure S12). Collectively, these data suggest that endothelial NOX5 induces endothelial dysfunction by uncoupling endothelial NOS, leading to impaired endothelium-dependent relaxation of muscular conduit arteries and ultimately to systolic hypertension (Figure 3C).

[0034] In summary, based on human genetic, human clinical, and genetic preclinical mechanistic validation, we report here the first identified causative molecular mechanism of age-associated human systolic hypertension. This endotype affects approximately 1 in 4 patients and is molecularly composed of NOX5-induced uncoupling of endothelial NO synthase and subsequent impaired endothelium-dependent vasodilation in muscular conduit arteries. Detecting elevated levels of NOX5 in circulating microparticles may serve as a mechanism-based liquid biopsy marker to stratify patients for therapeutic intervention. Based on our in vivo validation, such interventions may include the H4Bip precursor and NOS recoupler sepiapterin and NOX5 inhibitors (Altenhofer S, Kleikers PW, Radermacher KA, Scheurer P, Rob Hermans JJ, Schiffers P, et al. The NOX toolbox: validating the role of NADPH oxidases in physiology and disease. Cell Mol Life Sci. 2012;69(14):2327-43. Epub 2012 / 06 / 01. doi: 10.1007 / s00018-012-1010-9. PubMed PMID: 22648375; PubMed Central PMCID: PMCPMC3383958, Altenhofer S, Radermacher KA, Kleikers PW, Wingler K, Schmidt HH. Evolution of NADPH Oxidase Inhibitors: Selectivity and Mechanisms for Target Engagement. Antioxid Redox Signal. 2015;23(5):406-27. doi: 10.1089 / ars.2013.5814. PubMed PMID: 24383718; PubMed Central PMCID: PMCPMC4543484, Augsburger F, Filippova A, Rasti D, Seredenina T, Lam M, Maghzal G, et al.Pharmacological characterization of the seven human NOX isoforms and their inhibitors. Redox Biol. 2019;26:101272. Epub 2019 / 07 / 23. doi: 10.1016 / j.redox.2019.101272. PubMed PMID: 31330481; PubMed Central PMCID: PMCPMC6658998、Dao VT, Elbatreek MH, Altenhofer S, Casas AI, Pachado MP, Neullens CT, et al. Isoform-selective NADPH oxidase inhibitor panel for pharmacological target validation. Free Radic Biol Med. 2019. Epub 2019 / 12 / 29. doi: 10.1016 / j.freeradbiomed.2019.12.038. PubMed PMID: 31883469)。.

[0035] Here, we used a KI mouse model expressing human NOX5 in endothelial cells and leukocytes, which closely mimics the physiological pattern of NOX5 expression in humans (Casas AI, Kleikers PW, Geuss E, Langhauser F, Adler T, Busch DH, et al. Calcium-dependent blood-brain barrier breakdown by NOX5 limits postreperfusion benefit in stroke. J Clin Invest. 2019;130:1772-8. Epub 2019 / 03 / 19. doi: 10.1172 / JCI124283. PubMed PMID: 30882367; PubMed Central PMCID: PMCPMC6436900). Expression of human NOX5 in mice led to severe systolic hypertension with aging. This was not due to stiffening, structural tissue remodeling, or increased sensitivity to vasoconstrictor stimulation in the systemic arterial tree. Rather, this was due to a region-selective and specific attenuation of NO-mediated endothelium-dependent relaxation in medium-sized muscular conduit arteries via NOS uncoupling.

[0036] Collectively, our data justify proof-of-concept clinical trials targeting theragnostic strategies (Frangos S, Buscombe JR. Why should we be concerned about a “g”? European Journal of Nuclear Medicine and Molecular Imaging. 2019;46(2):519-. doi: 10.1007 / s00259-018-4204-z) in carefully stratified hypertensive patients based on detection of elevated NOX5, e.g., ROS overproduction due to oxidatively modified proteins, and mechanism-based functional restoration by a network pharmacology approach that inhibits NOX5 and recouples NOS. This marks the first molecular redefinition of the disease definition of the essential primary hypertension phenotype and represents a first step toward precision medicine in a currently high-demand indication. This could potentially apply to approximately one-quarter of all hypertensive patients.

[0037] Hypertension is a major risk factor (Hornsten C, Weidung B, Littbrand H, Carlberg B, Nordstrom P, Lovheim H, et al. High blood pressure as a risk factor for incident stroke among very old people: a population-based cohort study. J Hypertens. 2016;34(10):2059-65. Epub 2016 / 07 / 20. doi: 10.1097 / HJH.0000000000001048. PubMed PMID: 27434102; PubMed Central PMCID: PMCPMC5398900). NOX5 is also associated with poor prognosis in stroke (Casas AI, Kleikers PW, Geuss E, Langhauser F, Adler T, Busch DH, et al. Calcium-dependent blood-brain barrier breakdown by NOX5 limits postreperfusion benefit in Stroke. J Clin Invest. 2019;130:1772-8. Epub 2019 / 03 / 19. doi: 10.1172 / JCI124283. PubMed PMID: 30882367; PubMed Central PMCID: PMCPMC6436900) and correlates with atherosclerosis (Guzik TJ, Chen W, Gongora MC, Guzik B, Lob HE, Mangalat D, et al. Calcium-dependent NOX5 nicotinamide adenine dinucleotide phosphate oxidase contributes to vascular oxidative stress in human coronary artery disease. J Am Coll Cardiol. 2008;52(22):1803-9. Epub 2008 / 11 / 22. doi: 10.1016 / j.jacc.2008.07.063.PubMed PMID: 19022160; PubMed Central PMCID: PMCPMC2593790), this approach may not only lower blood pressure but also reduce stroke and myocardial infarction, two major consequences of hypertension.

[0038] On a broader scale, our triple interactome-based approach for disease module discovery, preclinical validation, and clinical validation may be applicable to a wide range of common or complex diseases. Here, we identify NOX5 as the missing link between impaired ROS and NO signaling. The complete module consists of NOX5, NOS3, different subunits of the NO receptor sGC, and the phosphodiesterases PDE5 and PDE9, in addition to the cGMP-dependent protein kinase PKG1. Dysregulation of such a module may be best treated with multiple drugs targeting different protein components. In this case, WT mice were treated with pharmacological NOX5 inhibition and sepiapterin, mimicking NOS recoupling.

[0039] Disease module construction is a young research field at the interface of biomedicine and bioinformatics. We started with a seed gene-based approach based on clinically validated proteins.NOX has been implicated by GWAS in elderly patients (Kraja AT, Cook JP, Warren HR, Surendran P, Liu C, Evangelou E, et al. New Blood Pressure-Associated Loci Identified in Meta-Analyses of 475 000 Individuals. Circ Cardiovasc Genet. 2017;10(5). Epub 2017 / 10 / 17. doi: 10.1161 / CIRCGENETICS.117.001778. PubMed PMID: 29030403; PubMed Central PMCID: PMCPMC5776077), but not in younger patients (Li H, Han X, Hu Z, Huang J, Chen J, Hixson JE, et al. Associations of NADPH oxidase-related genes with blood pressure changes and incident hypertension: The GenSalt Study. J Hum Hypertens. 2018;32(4):287-93. Epub 2018 / 02 / 22. doi: 10.1038 / s41371-018-0041-6. PubMed PMID: 29463833; PubMed Central PMCID: PMCPMC5889722), the only known enzyme family dedicated to ROS formation (Elbatreek MH, Pachado MP, Cuadrado A, Jandeleit-Dahm K, Schmidt H. Reactive Oxygen Comes of Age: Mechanism-Based Therapy of Diabetic End-Organ Damage. Trends Endocrinol Metab. 2019. Epub 2019 / 04 / 01. doi: 10.1016 / j.tem.2019.02.006. PubMed PMID: 30928357).The NO-cGMP pathway is critical for blood pressure regulation and its dysfunction, a hallmark of hypertension (Hermann M, Flammer A, Lüscher TF. Nitric oxide in hypertension. J Clin Hypertens (Greenwich). 2006;8(12 Suppl 4):17-29. Epub 2006 / 12 / 16. doi: 10.1111 / j.1524-6175.2006.06032.x. PubMed PMID: 17170603). Our approach uncovered a module containing a full complement of NO-cGMP signaling components, importantly with Nox5 as the sole ROS source. We independently confirmed these findings using two complementary in silico network module discovery approaches.

[0040] Endothelial microparticles are a well-established surrogate biomarker associated with hypertension and its progression (Helbing T, Olivier C, Bode C, Moser M, Diehl P. Role of microparticles in endothelial dysfunction and arterial hypertension. World J Cardiol. 2014;6(11):1135-9. Epub 2014 / 11 / 28. doi: 10.4330 / wjc.v6.i11.1135. PubMed PMID: 25429325; PubMed Central PMCID: PMCPMC4244610, Shantsila E. Endothelial microparticles: a universal marker of vascular health? J Hum Hypertens. 2009;23(5):359-61. Epub 2008 / 11 / 21. doi: 10.1038 / jhh.2008.138. PubMed PMID: 19020535). They generate ROS, contain NOX, induce endothelial dysfunction, and impair endothelium-dependent relaxation (Burger D, Turner M, Munkonda MN, Touyz RM. Endothelial Microparticle-Derived Reactive Oxygen Species: Role in Endothelial Signaling and Vascular Function. Oxid Med Cell Longev. 2016;2016:5047954. Epub 2016 / 06 / 18. doi: 10.1155 / 2016 / 5047954.PubMed PMID: 27313830; PubMed Central PMCID: PMCPMC4893592). In human endothelial cells, angiotensin II, the target of clinically used angiotensin type 1 receptor blockers and angiotensin-converting enzyme inhibitors, and endothelin-1, a prohypertensive autacoid, increase NOX5 expression (gene and protein) and activity (Montezano AC, Burger D, Paravicini TM, Chignalia AZ, Yusuf H, Almasri M, et al. Nicotinamide adenine dinucleotide phosphate reduced oxidase 5 (Nox5) regulation by angiotensin II and endothelin-1 is mediated via calcium / calmodulin-dependent, rac-1-independent pathways in human endothelial cells. Circ Res. 2010;106(8):1363-73. Epub 2010 / 03 / 27. doi: 10.1161 / CIRCRESAHA.109.216036. PubMed PMID: 20339118; PubMed Central PMCID: PMCPMC3119893). In addition to its physiological vascular expression in endothelial cells, NOX5 is also elevated to higher levels in human renal proximal tubule cells from patients with hypertension (Yu P, Han W, Villar VA, Yang Y, Lu Q, Lee H, et al. Unique role of NADPH oxidase 5 in oxidative stress in human renal proximal tubule cells. Redox Biol. 2014;2:570-9. Epub 2014 / 04 / 02. doi: 10.1016 / j.redox.2014.01.020).PubMed PMID: 24688893; PubMed Central PMCID: PMCPMC3969603), which may contribute to the observed correlation between NOX5, blood pressure, and microalbuminuria. Although induction of NOX5 in smooth muscle cells does not cause hypertension per se, it correlates with the progression of atherosclerotic lesions, and diseased coronary arteries exhibit elevated NOX5 expression and activity (Guzik TJ, Chen W, Gongora MC, Guzik B, Lob HE, Mangalat D, et al. Calcium-dependent NOX5 nicotinamide adenine dinucleotide phosphate oxidase contributes to vascular oxidative stress in human coronary artery disease. J Am Coll Cardiol. 2008;52(22):1803-9. Epub 2008 / 11 / 22. doi: 10.1016 / j.jacc.2008.07.063. PubMed PMID: 19022160; PubMed Central PMCID: PMCPMC2593790). Hypertension is a fairly comprehensive term that encompasses different mechanisms of elevated blood pressure. Some of these may be associated with poor clinical outcomes, while others may not. However, NOX5-dependent hypertension suggests that this molecular mechanism may also contribute to hypertension-related clinical outcomes, including stroke (Casas AI, Kleikers PW, Geuss E, Langhauser F, Adler T, Busch DH, et al. Calcium-dependent blood-brain barrier breakdown by NOX5 limits postreperfusion benefit in stroke. J Clin Invest. 2019;130:1772-8. Epub 2019 / 03 / 19. doi: 10.1172 / JCI124283).NOX5 expression is increased in intramyocardial blood vessels and cardiomyocytes after acute myocardial infarction in humans. Am J Pathol. 2012;180(6):2222-9. Epub 2012 / 04 / 17. doi: 10.1016 / j.ajpath.2012.02.018. PubMed PMID: 22503554) and renal failure (Yu P, Han W, Villar VA, Yang Y, Lu Q, Lee H, et al. Unique role of NADPH oxidase 5 in oxidative stress in human renal proximal tubule cells. Redox Biol. 2014;2:570-9. Epub 2014 / 04 / 02. doi: 10.1016 / j.redox.2014.01.020. PubMed PMID: 24688893; PubMed Central PMCID: PMCPMC3969603, Holterman CE, Thibodeau JF, Kennedy CR. NADPH oxidase 5 and renal disease. Curr Opin Nephrol Hypertens. 2015;24(1):81-7. Epub 2014 / 11 / 22. doi: 10.1097 / MNH.0000000000000081. PubMed PMID: 25415612), and thus appear to be associated with disease. .

[0041] GWAS has proposed two NOX candidate genes, Nox4 and Nox5. Nox4 knockout is not associated with a blood pressure phenotype (Kleinschnitz C, Grund H, Wingler K, Armitage ME, Jones E, Mittal M, et al. Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS biology. 2010;8(9). Epub 2010 / 09 / 30. doi: 10.1371 / journal.pbio.1000479. PubMed PMID: 20877715, Bouabout G, Ayme-Dietrich E, Jacob H, Champy MF, Birling MC, Pavlovic G, et al. Nox4 genetic inhibition in experimental hypertension and metabolic syndrome. Arch Cardiovasc Dis. 2018;111(1):41-52. Epub 2017 / 11 / 09. doi: 10.1016 / j.acvd.2017.03.011. PubMed PMID: 29113787), whereas in many models, Nox4 was rather vasoprotective (Ray R, Murdoch CE, Wang M, Santos CX, Zhang M, Alom-Ruiz S, et al. Endothelial Nox4 NADPH oxidase enhances vasodilatation and reduces blood pressure in vivo. Arterioscler Thromb Vasc Biol. 2011;31(6):1368-76. Epub 2011 / 03 / 19. doi: 10.1161 / ATVBAHA.110.219238. PubMed PMID: 21415386, Schroder K, Zhang M, Benkhoff S, Mieth A, Pliquett R, Kosowski J, et al.Nox4 is a protective reactive oxygen species generating vascular NADPH oxidase. Circ Res. 2012;110(9):1217-25. Epub 2012 / 03 / 30. doi: 10.1161 / CIRCRESAHA.112.267054. PubMed PMID: 22456182, Veith C, Kraut S, Wilhelm J, Sommer N, Quanz K, Seeger W, et al. NADPH oxidase 4 is not involved in hypoxia-induced pulmonary hypertension. Pulm Circ. 2016;6(3):397-400. Epub 2016 / 09 / 30. doi: 10.1086 / 687756. PubMed PMID: 27683617; PubMed Central PMCID: PMCPMC5019094). H2O2, a product of the NOX4 enzyme reaction, activates NOS (Brandes RP, Takac I, Schroder K. No superoxide—no stress?: Nox4, the good NADPH oxidase! Arterioscler Thromb Vasc Biol. 2011;31(6):1255-7. Epub 2011 / 05 / 20. doi: 10.1161 / ATVBAHA.111.226894. PubMed PMID: 21593458), which itself is another endothelium-derived relaxing factor (Miura H, Bosnjak JJ, Ning G, Saito T, Miura M, Gutterman DD. Role for hydrogen peroxide in flow-induced dilation of human coronary arterioles. Circ Res. 2003;92(2):e31-40. Epub 2003 / 02 / 08). doi: 10.1161 / 01.res.0000054200.44505.ab.PubMed PMID: 12574154, Leurgans TM, Bloksgaard M, Brewer JR, Bagatolli LA, Fredgart MH, Rosenstand K, et al. Endothelin-1 shifts the mediator of bradykinin-induced relaxation from NO to H2O2in resistance arteries from patients with cardiovascular disease. Br J Pharmacol. 2016;173(10):1653-64. Epub 2016 / 02 / 26. doi: 10.1111 / bph.13467. PubMed PMID: 26914408; PubMed Central PMCID: PMCPMC4842913, Shimokawa H. Hydrogen peroxide as an endothelium-derived hyperpolarizing factor. Pflugers Arch. 2010;459(6):915-22. Epub 2010 / 02 / 09. doi: 10.1007 / s00424-010-0790-8. PubMed PMID: 20140449). This made Nox5 a candidate gene, and first-neighbor analysis linking it to NO-cGMP signaling confirmed this. Unlike NOX4, NOX5 inhibits vasodilation in a sepiapterin-reversible manner (Mitchell BM, Dorrance AM, Webb RC. GTP cyclohydrolase 1 inhibition attenuates vasodilation and increases blood pressure in rats. Am J Physiol Heart Circ Physiol. 2003;285(5):H2165-70. Epub 2003 / 07 / 12. doi: 10.1152 / ajpheart.00253.2003).PubMed PMID: 12855421) generates superoxide, which can uncouple endothelial nitric oxide synthase in hypertension (Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest. 2003;111(8):1201-9. Epub 2003 / 04 / 17. doi: 10.1172 / JCI14172. PubMed PMID: 12697739; PubMed Central PMCID: PMCPMC152929, Dumitrescu C, Biondi R, Xia Y, Cardounel AJ, Druhan LJ, Ambrosio G, et al. Myocardial ischemia results in tetrahydrobiopterin (BH4) oxidation with impaired endothelial function ameliorated by BH4. Proc Natl Acad Sci US A. 2007;104(38):15081-6. Epub 2007 / 09 / 13. doi: 10.1073 / pnas.0702986104. PubMed PMID: 17848522; PubMed Central PMCID: PMCPMC1986616). A mechanistic investigation into this role of NOX5 in hypertension was conducted in a preclinical mouse KI model expressing NOX5, a gene not present in the mouse genome, in a physiological cell type, endothelial cells, where NOX5 is important for endothelial migration and angiogenesis (Pi X, Xie L, Portbury AL, Kumar S, Lockyer P, Li X, et al.NADPH oxidase-generated reactive oxygen species are required for stromal cell-derived factor-1alphastimulated angiogenesis. Arterioscler Thromb Vasc Biol. 2014;34(9):2023-32. Epub 2014 / 07 / 06. doi: 10.1161 / ATVBAHA.114.303733. PubMed PMID: 24990230; PubMed Central PMCID: PMCPMC4149803). In mice expressing non-physiological levels of NOX5 in smooth muscle cells, blood pressure is normal and angiotensin II-induced compressive effects are not augmented (Montezano AC, De Lucca Camargo L, Persson P, Rios FJ, Harvey AP, Anagnostopoulou A, et al. NADPH Oxidase 5 Is a Pro-Contractile Nox Isoform and a Point of Cross-Talk for Calcium and Redox Signaling—Implications in Vascular Function. J Am Heart Assoc. 2018;7(12). Epub 2018 / 06 / 17. doi: 10.1161 / JAHA.118.009388. PubMed PMID: 29907654; PubMed Central PMCID: PMCPMC6220544). Of particular interest was the region-selective effect of NOX5, which hinted at vascular heterogeneity in aging endothelial cell dysfunction (Barton M, Cosentino F, Brandes RP, Moreau P, Shaw S, Luscher TF. Anatomic heterogeneity of vascular aging: role of nitric oxide and endothelin. Hypertension. 1997;30(4):817-24. Epub 1997 / 10 / 23. doi: 10.1161 / 01.hyp.30.4).817. PubMed PMID: 9336378, Matz RL, de Sotomayor MA, Schott C, Stoclet JC, Andriantsitohaina R. Vascular bed heterogeneity in age-related endothelial dysfunction with respect to NO and eicosanoids. Br J Pharmacol. 2000;131(2):303-11. Epub 2000 / 09 / 19. doi: 10.1038 / sj.bjp.0703568. PubMed PMID: 10991924; PubMed Central PMCID: PMCPMC1572322). NOX5 is present in the muscular femoral conduit arteries of KI mice but not in the small, resistance-sized saphenous arteries, potentially leading to selective systolic hypertension with elevated arterial pulse pressure. This effect was not reversed in our ex vivo experiments with antioxidants, possibly because NOS uncoupling was already chronically established in vivo by NOX5-derived superoxide. Preclinical studies have shown that sepiapterin or H4Bip reduces elevated blood pressure induced by NOS uncoupling (Wang S, Xu J, Song P, Wu Y, Zhang J, Chul Choi H, et al. Acute inhibition of guanosine triphosphate cyclohydrolase 1 uncouples endothelial nitric oxide synthase and elevates blood pressure. Hypertension. 2008;52(3):484-90. Epub 2008 / 07 / 23. doi: 10.1161 / HYPERTENSIONAHA.108.112094. PubMed PMID: 18645049; PubMed Central PMCID: PMCPMC3523107, Podjarny E, Hasdan G, Bernheim J, Rashid G, Green J, Korzets Z, et al.Effect of chronic tetrahydrobiopterin supplementation on blood pressure and proteinuria in 5 / 6 nephrectomized rats. Nephrol Dial Transplant. 2004;19(9):2223-7. Epub 2004 / 07 / 15. doi: 10.1093 / ndt / gfh383. PubMed PMID: 15252157)。.

[0042] Regarding the clinical dimension of our findings, our observation of elevated plasma ADMA levels in hypertensive patients supports NOS uncoupling (Perticone F, Sciacqua A, Maio R, Perticone M, Maas R, Boger RH, et al. Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential primary hypertension. J Am Coll Cardiol. 2005;46(3):518-23. Epub 2005 / 08 / 02. doi: 10.1016 / j.jacc.2005.04.040. PubMed PMID: 16053968, Sonmez A, Celebi G, Erdem G, Tapan S, Genc H, Tasci I, et al. Plasma apelin and ADMA Levels in patients with essential primary hypertension. Clin Exp Hypertens. 2010;32(3):179-83. Epub 2010 / 05 / 28. doi: 10.3109 / 10641960903254505. PubMed PMID: 20504125), a mechanistic link with NOX5 similar to what we have obtained preclinically in NOX5 KI mice will likely require ex vivo analysis of isolated human vessels or interventional trials with sepiapterin.Indeed, sepiapterin analogues, namely folic acid and H4Bip, are clinically effective in reducing elevated blood pressure by improving endothelial function (Porkert M, Sher S, Reddy U, Cheema F, Niessner C, Kolm P, et al. Tetrahydrobiopterin: a novel antihypertensive therapy. J Hum Hypertens. 2008;22(6):401-7. Epub 2008 / 03 / 07. doi: 10.1038 / sj.jhh.1002329. PubMed PMID: 18322548, McRae MP. High-dose folic acid supplementation effects on endothelial function and blood pressure in hypertensive patients: a meta-analysis of randomized controlled clinical trials. J Chiropr Med. 2009;8(1):15-24. Epub 2009 / 08 / 04. doi: 10.1016 / j.jcm.2008.09.001. PubMed PMID: 19646382; PubMed Central PMCID: PMCPMC2697578).Folic acid was used alone (Kong X, Huang X, Zhao M, Xu B, Xu R, Song Y, et al. Platelet Count Effects Efficacy of Folic Acid in Preventing First Stroke. J Am Coll Cardiol. 2018;71(19):2136-46. Epub 2018 / 05 / 12. doi: 10.1016 / j.jacc.2018.02.072. PubMed PMID: 29747834) or in combination with antihypertensive drugs (Huo Y, Li J, Qin X, Huang Y, Wang X, Gottesman RF, et al. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. JAMA. 2015;313(13):1325-35. Epub 2015 / 03 / 17. doi: 10.1001 / jama.2015.2274. PubMed PMID: 25771069, Wang WW, Wang XS, Zhang ZR, He JC, Xie CL. A Meta-Analysis of Folic Acid in Combination with Anti-Hypertension Drugs in Patients with Hypertension and Hyperhomocysteinemia. Front Pharmacol. 2017;8:585. Epub 2017 / 09 / 16. doi: 10.3389 / fphar.2017.00585. PubMed PMID: 28912716; PubMed Central PMCID: PMCPMC5584015).

[0043] Overall, our findings, using an in silico network approach and further clinical and preclinical validation, explain the long-observed correlation between oxidative stress, endothelial dysfunction, and systolic hypertension. The humanized endothelial NOX5 KI mouse is the first mechanism-based animal model of human age-related hypertension and endothelial dysfunction. Ideally, NOX5 inhibition and NOS recoupling, combined with mechanistic biomarker stratification based on endothelial microparticle liquid biopsies, for example, represents a first-in-class mechanism-based approach for curative antihypertensive therapy, eliminating the need for symptomatic vasodilators.

[0044] In summary, hypertension is the most important cause of death and disability in the elderly. However, in 9 out of 10 cases, the molecular cause remains unknown. This group is usually referred to as primary arterial hypertension.

[0045] Herein, we identify the mechanisms behind at least the majority of cases of primary arterial hypertension that are still currently considered treatment-resistant hypertension.

[0046] We identified this mechanism as involving impaired endothelium-dependent vasodilation by reactive oxygen species (ROS). We found that ROS-forming Nox genes are associated with hypertension, and herein we identify Nox5, absent in rodents, as the sole neighbor of vasodilatory endothelial nitric oxide (NO) signaling in humans.

[0047] We found that in hypertensive patients, endothelial microparticles contained higher levels of NOX5 with a bimodal distribution, correlating with disease severity.

[0048] It was believed that subjects with high circulating NOX5 levels could be effectively treated with a NOX5 inhibitor or a compound selected from the group consisting of sepiapterin, L-citrulline, L-arginine, tetrahydrobiopterin, and folic acid. One example of a suitable NOX5 inhibitor is ML090.

[0049] We found that mice expressing human NOX5 in endothelial cells develop severe systolic hypertension and impaired endothelium-dependent vasodilation during aging, due to uncoupled NO synthase. We conclude that NOX5-induced uncoupling of endothelial NO synthase is a causative mechanism and therapeutic target for the age-related hypertensive endotype. We conclude that Nox5 knock-in mice are the first mechanism-based animal model of hypertension.

[0050] Therefore, in one embodiment, the present invention relates to a novel method for diagnosing essential arterial hypertension in a subject, wherein the level of NADPH oxidase 5 (NOX5) is determined in a body fluid or tissue sample from the subject, and if the level of NOX5 is above a predetermined threshold level, it is concluded that the subject has (NOX5-dependent) essential arterial hypertension. This method identifies subjects with a disease previously called treatment-resistant hypertension. These cases can now be effectively treated with a NOX5 inhibitor or a compound selected from the group consisting of sepiapterin, L-citrulline, L-arginine, tetrahydrobiopterin, and folic acid. These cases are identified as having the molecular structure (I):

[0051] [ka]

[0052] These patients can now be effectively treated with the NOX5 inhibitor ML090 (5,12-dihydroquinoxalino(2,3-B)quinoxaline), which has the following structure:

[0053] The present invention further relates to a method for diagnosing NOX5-dependent hypertension in a subject by testing for the presence of a nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 5 (NOX5) concentration of at least 160 pg per ml in a plasma sample obtained from a subject suffering from essential arterial hypertension.

[0054] In an exemplary embodiment, the diagnostic method of the present invention comprises: (a) isolating endothelial microparticles from a plasma sample; (b) measuring NOX5 in the endothelial microparticles of step (a) using a protein detection assay to determine the concentration of NOX5 in the plasma sample as pg of NOX5 per ml of plasma sample; and the (human) subject is diagnosed as suffering from NOX5-dependent hypertension if the concentration of NOX5 determined in step (b) is at least 160 pg NOX5 per ml of said plasma sample.

[0055] In a further embodiment, the present invention provides a method for diagnosing NOX5-dependent hypertension in a subject by testing for the presence of a nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 5 (NOX5) concentration of at least 160 pg per ml in a plasma sample obtained from a subject suffering from essential arterial hypertension, wherein the subject suffers from hypertension defined as a systolic blood pressure of at least 140 mmHg, a diastolic blood pressure of at least 90 mmHg, or the use of antihypertensive medication.

[0056] In a further embodiment, the present invention provides a method for diagnosing nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 5 (NOX5)-dependent hypertension in a subject by testing for the presence of a nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 5 (NOX5) concentration of at least 160 pg per ml in a plasma sample obtained from a subject suffering from essential arterial hypertension, wherein the subject does not have a history or clinical evidence of any of the following: angina, myocardial infarction, congestive heart failure, peripheral vascular disease, inflammatory disease, and any disease predisposing to vasculitis, and the subject does not have stage 4 or stage 5 chronic kidney disease.

[0057] The present invention further relates to a method for diagnosing NOX5-dependent hypertension in a subject, comprising determining the level of NOX5 in a body fluid or tissue sample from the subject, wherein if the level of NOX5 is greater than 160 pg per ml, it is concluded that the subject has NOX5-dependent hypertension.

[0058] In a further embodiment, the present invention relates to a method for diagnosing NOX5-dependent hypertension in a subject, comprising determining the level of NOX5 in a body fluid or tissue sample from the subject, wherein if the level of NOX5 is greater than 160 pg per ml, it is concluded that the subject has NOX5-dependent hypertension, and the body fluid or tissue sample is a plasma sample.

[0059] In a further embodiment, the present invention provides a method for diagnosing NOX5-dependent hypertension in a subject, comprising determining the level of NOX5 in a body fluid sample or tissue sample from the subject, wherein if the level of NOX5 is greater than 160 pg per ml, it is concluded that the subject has NOX5-dependent hypertension, and the subject is suffering from hypertension defined as a systolic blood pressure of at least 140 mmHg, a diastolic blood pressure of at least 90 mmHg, or the use of antihypertensive medication.

[0060] In an exemplary embodiment, the diagnostic method of the present invention comprises: (a) isolating endothelial microparticles from a plasma sample; (b) measuring NOX5 in the endothelial microparticles of step (a) using a protein detection assay to determine the concentration of NOX5 in the plasma sample as pg of NOX5 per ml of plasma sample; and the (human) subject is diagnosed as suffering from NOX5-dependent hypertension if the concentration of NOX5 determined in step (b) is at least 160 pg NOX5 per ml of said plasma sample.

[0061] In a further embodiment, the present invention provides a method for diagnosing NOX5-dependent hypertension in a subject, comprising determining the level of NOX5 in a body fluid sample or tissue sample from the subject, wherein if the level of NOX5 is greater than 160 pg per ml, it is concluded that the subject has NOX5-dependent hypertension, and the subject does not have a history or clinical evidence of any of the following: angina, myocardial infarction, congestive heart failure, peripheral vascular disease, inflammatory disease, and any disease that predisposes to vasculitis, and the subject does not have stage 4 or stage 5 chronic kidney disease.

[0062] The present invention further relates to a compound selected from the group consisting of sepiapterin, L-citrulline, L-arginine, tetrahydrobiopterin, folic acid and a NOX5 inhibitor, particularly the NOX5 inhibitor 5,12-dihydroquinoxalino(2,3-B)quinoxaline (ML090), for use in treating a subject with essential arterial hypertension, particularly NOX5-dependent hypertension.

[0063] The present invention further relates to a compound selected from sepiapterin, folic acid, L-citrulline, L-arginine and tetrahydrobiopterin for use in a method for treating a subject with essential arterial hypertension, wherein the subject with essential arterial hypertension has a NOX5 plasma concentration of at least 160 pg NOX5 per ml of plasma.

[0064] In a further embodiment, the present invention further relates to a compound selected from sepiapterin, folic acid, L-citrulline, L-arginine and tetrahydrobiopterin for use in a method for treating a subject with essential arterial hypertension, wherein the subject with essential arterial hypertension is characterized by having a NOX5 plasma concentration of at least 160 pg of NOX5 per ml of plasma, and the essential arterial hypertension is NOX5-dependent hypertension.

[0065] In a further embodiment, the present invention relates to a compound selected from sepiapterin, folic acid, L-citrulline, L-arginine and tetrahydrobiopterin for use in a method for treating a subject with essential arterial hypertension, wherein the compound is sepiapterin, characterized in that the subject with essential arterial hypertension has a NOX5 plasma concentration of at least 160 pg NOX5 per ml of plasma.

[0066] In a further embodiment, the present invention relates to a compound selected from sepiapterin, folic acid, L-citrulline, L-arginine and tetrahydrobiopterin for use in a method for treating a subject with essential arterial hypertension, wherein said subject with essential arterial hypertension has a NOX5 plasma concentration of at least 160 pg NOX5 per ml of plasma, and said subject has moderately elevated albuminuria, defined as an albumin excretion rate of 20 to 200 mg per minute.

[0067] In a further embodiment, the present invention relates to a compound selected from sepiapterin, folic acid, L-citrulline, L-arginine and tetrahydrobiopterin for use in a method for treating a subject with essential arterial hypertension, wherein the subject with essential arterial hypertension is characterized by having a NOX5 plasma concentration of at least 160 pg of NOX5 per ml of plasma, and the subject is diagnosed as suffering from NOX5-dependent hypertension by at least one of the methods of the present invention.

[0068] In a further embodiment, the present invention relates to a compound selected from sepiapterin, folic acid, L-citrulline, L-arginine and tetrahydrobiopterin for use in a method for treating a subject with essential arterial hypertension, wherein the subject with essential arterial hypertension is characterized by having a NOX5 plasma concentration of at least 160 pg NOX5 per ml of plasma, and the subject is at least 53 years old.

[0069] In a further embodiment, the present invention relates to a compound selected from sepiapterin, folic acid, L-citrulline, L-arginine and tetrahydrobiopterin for use in a method for treating a subject with essential arterial hypertension, wherein the subject with essential arterial hypertension is characterized by having a NOX5 plasma concentration of at least 160 pg NOX5 per ml of plasma, and the subject is at least 57 years old.

[0070] In a further embodiment, the present invention relates to a compound selected from sepiapterin, folic acid, L-citrulline, L-arginine and tetrahydrobiopterin for use in a method for treating a subject with essential arterial hypertension, wherein the subject with essential arterial hypertension has a NOX5 plasma concentration of at least 160 pg of NOX5 per ml of plasma, and the subject has a higher plasma concentration of asymmetric dimethylarginine compared to the mean plasma concentration of asymmetric dimethylarginine in a group of healthy subjects.

[0071] In a further embodiment, the present invention relates to a compound selected from sepiapterin, folic acid, L-citrulline, L-arginine and tetrahydrobiopterin for use in a method for treating a subject with essential arterial hypertension, wherein the subject with essential arterial hypertension has a NOX5 plasma concentration of at least 160 pg of NOX5 per ml of plasma, and the subject has a plasma concentration of asymmetric dimethylarginine of at least 0.53 micromoles per liter, preferably at least 0.58 micromoles per liter, more preferably at least 0.63 micromoles per liter.

[0072] In a further embodiment, the present invention relates to a compound selected from sepiapterin, folic acid, L-citrulline, L-arginine and tetrahydrobiopterin for use in a method for treating a subject with essential arterial hypertension, wherein the subject with essential arterial hypertension is characterized by having a NOX5 plasma concentration of at least 160 pg NOX5 per ml of plasma, and the subject is suffering from hypertension defined as a systolic blood pressure of at least 140 mmHg, a diastolic blood pressure of at least 90 mmHg, or the use of antihypertensive medication.

[0073] The present invention further relates to a compound selected from sepiapterin, folic acid, L-citrulline, L-arginine, and tetrahydrobiopterin for use in a method of treating a subject with treatment-resistant hypertension.

[0074] In a further embodiment, the present invention relates to a compound selected from sepiapterin, folic acid, L-citrulline, L-arginine and tetrahydrobiopterin for use in a method for treating a subject with treatment-resistant hypertension, wherein the subject has a NOX5 plasma concentration of at least 160 pg NOX5 per ml of plasma.

[0075] In a further embodiment, the present invention relates to a compound selected from sepiapterin, folic acid, L-citrulline, L-arginine and tetrahydrobiopterin, wherein the compound is sepiapterin, for use in a method of treating a subject with treatment-resistant hypertension.

[0076] In a further embodiment, the present invention relates to a compound selected from sepiapterin, folic acid, L-citrulline, L-arginine, and tetrahydrobiopterin, for use in a method of treating a subject with treatment-resistant hypertension, wherein the subject has moderately elevated albuminuria, defined as an albumin excretion rate of 20 to 200 mg per minute.

[0077] In a further embodiment, the present invention relates to a compound selected from sepiapterin, folic acid, L-citrulline, L-arginine and tetrahydrobiopterin for use in a method for treating a subject with treatment-resistant hypertension, wherein the subject is diagnosed as suffering from NOX5-dependent hypertension by at least one of the methods of the present invention.

[0078] In a further embodiment, the present invention relates to a compound selected from sepiapterin, folic acid, L-citrulline, L-arginine, and tetrahydrobiopterin for use in a method of treating a subject having treatment-resistant hypertension, wherein the subject is at least 53 years of age.

[0079] In a further embodiment, the present invention relates to a compound selected from sepiapterin, folic acid, L-citrulline, L-arginine, and tetrahydrobiopterin for use in a method of treating a subject having treatment-resistant hypertension, wherein the subject is at least 57 years of age.

[0080] In a further embodiment, the present invention relates to a compound selected from sepiapterin, folic acid, L-citrulline, L-arginine and tetrahydrobiopterin for use in a method for treating a subject with treatment-resistant hypertension, wherein the subject has a plasma concentration of asymmetric dimethylarginine that is higher than the mean plasma concentration of asymmetric dimethylarginine in a group of healthy subjects.

[0081] In a further embodiment, the present invention relates to a compound selected from sepiapterin, folic acid, L-citrulline, L-arginine, and tetrahydrobiopterin for use in a method of treating a subject with treatment-resistant hypertension, wherein said subject has a plasma concentration of asymmetric dimethylarginine of at least 0.53 micromoles per liter, preferably at least 0.58 micromoles per liter, and more preferably at least 0.63 micromoles per liter.

[0082] In a further embodiment, the present invention relates to a compound selected from sepiapterin, folic acid, L-citrulline, L-arginine, and tetrahydrobiopterin for use in a method of treating a subject with treatment-resistant hypertension, wherein the subject is afflicted with hypertension defined as a systolic blood pressure of at least 140 mmHg, a diastolic blood pressure of at least 90 mmHg, or the use of antihypertensive medication.

[0083] The present invention further relates to a compound selected from sepiapterin, folic acid, L-citrulline, L-arginine, and tetrahydrobiopterin for use in a method of treating a subject with NOX5-dependent hypertension.

[0084] In a further embodiment, the present invention relates to a compound selected from sepiapterin, folic acid, L-citrulline, L-arginine and tetrahydrobiopterin for use in a method for treating a subject having NOX5-dependent hypertension, wherein the subject has a NOX5 plasma concentration of at least 160 pg of NOX5 per ml of plasma.

[0085] In a further embodiment, the present invention relates to a compound selected from sepiapterin, folic acid, L-citrulline, L-arginine and tetrahydrobiopterin, wherein the compound is sepiapterin, for use in a method for treating a subject with NOX5-dependent hypertension.

[0086] In a further embodiment, the present invention relates to a compound selected from sepiapterin, folic acid, L-citrulline, L-arginine, and tetrahydrobiopterin, for use in a method of treating a subject having NOX5-dependent hypertension, wherein the subject has moderately elevated albuminuria, defined as an albumin excretion rate of 20 to 200 mg per minute.

[0087] In a further embodiment, the present invention relates to a compound selected from sepiapterin, folic acid, L-citrulline, L-arginine and tetrahydrobiopterin for use in a method for treating a subject having NOX5-dependent hypertension, wherein the subject is diagnosed as suffering from NOX5-dependent hypertension by at least one of the methods of the present invention.

[0088] In a further embodiment, the present invention relates to a compound selected from sepiapterin, folic acid, L-citrulline, L-arginine and tetrahydrobiopterin for use in a method for treating a subject having NOX5-dependent hypertension, wherein the subject is at least 53 years of age.

[0089] In a further embodiment, the present invention relates to a compound selected from sepiapterin, folic acid, L-citrulline, L-arginine and tetrahydrobiopterin for use in a method for treating a subject having NOX5-dependent hypertension, wherein the subject is at least 57 years old.

[0090] In a further embodiment, the present invention relates to a compound selected from sepiapterin, folic acid, L-citrulline, L-arginine and tetrahydrobiopterin for use in a method for treating a subject with NOX5-dependent hypertension, wherein the subject has a plasma concentration of asymmetric dimethylarginine that is higher than the mean plasma concentration of asymmetric dimethylarginine in a group of healthy subjects.

[0091] In a further embodiment, the present invention relates to a compound selected from sepiapterin, folic acid, L-citrulline, L-arginine and tetrahydrobiopterin for use in a method for treating a subject having NOX5-dependent hypertension, wherein the subject has a plasma concentration of asymmetric dimethylarginine of at least 0.53 micromoles per liter, preferably at least 0.58 micromoles per liter, and more preferably at least 0.63 micromoles per liter.

[0092] In a further embodiment, the present invention relates to a compound selected from sepiapterin, folic acid, L-citrulline, L-arginine and tetrahydrobiopterin for use in a method for treating a subject with NOX5-dependent hypertension, wherein the subject is suffering from hypertension defined as a systolic blood pressure of at least 140 mmHg, a diastolic blood pressure of at least 90 mmHg, or the use of antihypertensive medication.

[0093] The present invention also relates to the use of mice with a knock-in human Nox5 gene for the discovery and development of therapeutic agents for use in and methods for the detection of NOX5-dependent hypertension in a subject.

[0094] In a further embodiment, the present invention relates to the use of a mouse having a knock-in human Nox5 gene for discovering and developing therapeutic agents and methods for detection for use in NOX5-dependent hypertension in a subject, wherein the mouse is at least 68 weeks old.

[0095] In a further embodiment, the present invention relates to the use of a mouse having a knock-in human Nox5 gene for discovering and developing therapeutic agents and methods for detection for use in NOX5-dependent hypertension in a subject, wherein the mouse is a 129 / SV mouse.

[0096] In a further embodiment, the present invention relates to the use of a mouse having a knock-in human Nox5 gene for discovering and developing therapeutic agents and methods for detection for use in NOX5-dependent hypertension in a subject, wherein essential arterial hypertension is NOX5-dependent hypertension.

[0097] In a further embodiment, the present invention relates to the use of a mouse having a knock-in human Nox5 gene for discovering and developing therapeutic agents and methods for detection for use in NOX5-dependent hypertension in a subject, wherein the mouse has a genetic background comprising 80% 129 / SV.

[0098] In a further embodiment, the present invention relates to the use of a mouse having a knock-in human Nox5 gene for discovering and developing therapeutic agents and methods for detection for use in NOX5-dependent hypertension in a subject, wherein the mouse has a genetic background consisting of 80% 129 / SV and 20% C57BI6.

[0099] Thus, specifically, the mice have a mixed genetic background comprising 80% 129 / SV, and more specifically, the mice have a mixed genetic background consisting of 80% 129 / SV and 20% C57BI6.

[0100] Specifically, the mice have a mixed genetic background comprising 80% 129 / SV. More specifically, the mice have a mixed genetic background consisting of 80% 129 / SV and 20% C57BI6.

[0101] In a further embodiment, the present invention relates to the use of a mouse having a knock-in human Nox5 gene for discovering and developing therapeutic agents and methods for detection for use in NOX5-dependent hypertension in a subject, wherein the knock-in human Nox5 gene is controlled by the promoter tie 2.

[0102] In a further embodiment, the present invention relates to the use of a mouse having a knock-in human Nox5 gene for the discovery and development of therapeutic agents and detection methods for use in NOX5-dependent hypertension in a subject, wherein human NOX5 is expressed in endothelial cells and leukocytes of the mouse.

[0103] Specifically, the mice have a mixed genetic background comprising 80% 129 / SV. More specifically, the mice have a mixed genetic background consisting of 80% 129 / SV and 20% C57BI6.

[0104] One embodiment is the use of a mouse having a knock-in human Nox5 gene, wherein said knock-in human Nox5 gene is controlled by the promoter tie 2.

[0105] One embodiment is the use of a mouse having a knock-in human Nox5 gene, wherein human NOX5 is expressed in endothelial cells and leukocytes of said mouse.

[0106] In a further embodiment, the present invention relates to the above-described method, wherein the predetermined threshold level is the level of NOX5 determined in a sample collected using the same method from a healthy subject without essential arterial hypertension. In an even more preferred embodiment, the threshold level is 160 pg of NOX5 per ml. In an even more preferred embodiment, the subject also has microalbuminuria. The sample used in the methods described herein may be a body fluid sample or a tissue sample, and preferably, the sample contains vascular endothelial cells, and even more preferably, the sample contains circulating endothelial microparticles. In a further embodiment, the present invention provides the above-described method, wherein the level of NOX5 is determined by measuring the level of Nox5 messenger RNA.

[0107] In a further embodiment, the present invention provides the above method, wherein the level of NOX5 is determined by measuring the level of uncoupled nitric oxide synthase (NOS).

[0108] In a further embodiment, the present invention provides the above method, wherein the level of uncoupled NOS is determined by measuring the level of asymmetric dimethylarginine (ADMA).

[0109] In a further embodiment, the present invention provides a method as described above, wherein the sample is selected from the group comprising plasma, blood and serum.

[0110] In a further embodiment, the present invention provides the above method, wherein the sample comprises platelet-rich plasma containing leukocytes.

[0111] In a further embodiment, the present invention provides the above method, wherein the sample comprises platelet-poor plasma.

[0112] The present invention further relates to a compound selected from the group consisting of sepiapterin, L-citrulline, L-arginine, tetrahydrobiopterin, folic acid and a NOX5 inhibitor for use in treating a subject with essential arterial hypertension.

[0113] In a further embodiment, the present invention relates to a compound for the above uses, wherein prior to treatment, the subject is diagnosed with essential arterial hypertension using the methods described herein.

[0114] In a further embodiment, the present invention relates to a compound for the above uses, wherein treatment comprises administration to a subject of a compound selected from the group consisting of sepiapterin, L-citrulline, L-arginine, tetrahydrobiopterin, folic acid and a NOX5 inhibitor, wherein the compound is administered in an amount such that the level of the compound is normalized in the body fluid or tissue from which the sample was taken.

[0115] In a further embodiment, the present invention relates to a compound for the above uses, wherein the treatment comprises measuring the level of NOX5 as described herein.

[0116] In a further embodiment, the present invention relates to the use of aged NOX5 knock-in animal models for the discovery and development of therapeutic and diagnostic agents for use in NOX5 and uncoupled NOS-dependent essential arterial hypertension. [Example] [Example]

[0117] Research design. The sample size of human subjects was determined by G*Power software. For mice, we used a power analysis with the formula n = 2x s2x(Za / 2+Zb)2 / D2 (L. Sachs, Angewandte Statistik, Springer, 1983, Berlijn, Springer Verlag). Human subjects with a history or clinical evidence of angina, myocardial infarction, congestive heart failure, peripheral vascular disease, inflammatory disease, or any disease predisposing to vasculitis were excluded. Secondary causes of hypertension were excluded by appropriate investigation. Stage 4 and 5 chronic kidney disease (GFR < 30 mL / min / 1.73 m) was excluded. 2 Patients with HIV-1-associated leukemia (HLA-1) were also excluded. Human samples were assigned to different groups based on blood pressure and albuminuria levels. Mice were assigned to each experimental group according to their genotype. Investigators were blinded to the experimental groups. Repeated experiments were successful. All experiments were reproduced at least three times using independent biological samples. [Example]

[0118] In silico methods We extracted molecular subnetworks from experimentally validated protein-protein interactions from the IID (Kotlyar M, Pastrello C, Malik Z, Jurisica I. IID 2018 update: context-specific physical protein-protein interactions in human, model organisms and domesticated species. Nucleic Acids Res. 2019;47(D1):D581-D9. Epub 2018 / 11 / 09. doi: 10.1093 / nar / gky1037. PubMed PMID: 30407591; PubMed Central PMCID: PMCPMC6323934) database (interactome) using NOX family members and nitric oxide-cyclic GMP-related proteins as seed nodes. This seed set included NOX1, NOX3, NOX4, NOX5, NOS1, NOS3, GUCYA1, GUCYA2, GUCYB1, PDE5A, PDE9A, and PRKG1. We obtained a subnetwork derived from all first-neighbors of the seed genes from the interactome. The derived subnetwork was then pruned according to subnetwork participation (SPD), defined as the node degree in the subnetwork normalized by the node (protein) degree in the complete interactome. SPD quantifies how abundant a protein interaction is in a subnetwork. In this way, we identified weighted disease modules, represented by a set of connected components and several single nodes. We selected an SPD cutoff value for the pruning step corresponding to a cumulative sum of 80% of the node percentages, since this would include most module-specific interactions while excluding most nonspecific nodes. The final subnetwork consisted of 56 proteins and 83 protein-protein interactions.

[0119] Furthermore, we applied two top-ranked disease network module identification methods from the Module Identification DREAM Challenge (Choobdar S, Ahsen ME, Crawford J, Tomasoni M, Fang T, Lamparter D, et al. Assessment of network module identification across complex diseases. Nat Methods. 2019;16(9):843-52. Epub 2019 / 09 / 01. doi: 10.1038 / s41592-019-0509-5. PubMed PMID: 31471613; PubMed Central PMCID: PMCPMC6719725) to the interactome. We selected these methods from two complementary categories of methods: global and local. The main difference between these two methods is that global methods exploit the global structural information of the PPI network, whereas local methods only consider local neighbor information. The global modularity optimization method (M1) from the DREAM challenge included in the MONET tool and the agglomerative local method (L1) from the SPICi tool (Jiang P, Singh M. SPICi: a fast clustering algorithm for large biological networks. Bioinformatics. 2010;26(8):1105-11. Epub 2010 / 02 / 27. doi: 10.1093 / bioinformatics / btq078. PubMed PMID: 20185405; PubMed Central PMCID: PMCPMC2853685) were selected (with the best performance in their categories) and applied to find disease modules in the interactome.Note that M1 is an ensemble approach that combines multiple module detection algorithms to avoid suboptimal partitioning caused by individual algorithms (Arenas A, Fernandez A, Gomez S. Analysis of the structure of complex networks at different resolution levels. New Journal of Physics. 2008;10(5):053039. doi: 10.1088 / 1367-2630 / 10 / 5 / 053039), and works remarkably well in our tool even without any seed nodes. The agglomerative L1 method relentlessly clusters the network, starting from automatically selected local seeds with high weighted degrees. This algorithm improves the local density of modules in the vicinity of the seed nodes. [Example]

[0120] Human research participants We conducted a randomized controlled trial of 1000 patients with essential primary hypertension and 30 mL / min / 1.73 m at Taipei Veterans General Hospital from April 2008 to December 2008. 2Previous studies enrolling consecutive outpatients with a baseline estimated GFR of ≥ 100 mg / mL (Hsu CY, Huang PH, Chiang CH, Leu HB, Huang CC, Chen JW, et al. Increased circulating endothelial apoptotic microparticle to endothelial progenitor cell ratio is associated with subsequent decline in glomerular filtration rate in hypertensive patients. PLoS One. 2013;8(7):e68644. Epub 2013 / 07 / 23. doi: 10.1371 / journal.pone.0068644. PubMed PMID: 23874701; PubMed Central PMCID: PMCPMC3709900, Huang PH, Huang SS, Chen YH, Lin CP, Chiang KH, Chen JS, et al. Increased circulating CD31+ / annexin V+ apoptotic This study was designed based on the findings of the National Institute of Cardiovascular Diseases (NIH)

[1999] . (microparticles and decreased circulating endothelial progenitor cell levels in hypertensive patients with microalbuminuria. J Hypertens. 2010;28(8):1655-65. Epub 2010 / 06 / 04. doi: 10.1097 / HJH.0b013e32833a4d0a. PubMed PMID: 20520578). Hypertension was defined as a systolic blood pressure of 140 mmHg or greater, a diastolic blood pressure of 90 mmHg or greater, or the use of antihypertensive medication. In accordance with one embodiment of the present invention, a method for diagnosing essential arterial hypertension in a subject, particularly NOX5-dependent hypertension in a subject, was provided, wherein the subject suffers from hypertension defined as a systolic blood pressure of at least 140 mmHg, a diastolic blood pressure of at least 90 mmHg, or the use of antihypertensive medication.

[0121] Subjects with a history or clinical evidence of angina, myocardial infarction, congestive heart failure, peripheral vascular disease, inflammatory disease, or any disease predisposing to vasculitis were excluded. Secondary causes of hypertension were excluded by appropriate investigation. Stage 4 and 5 chronic kidney disease (GFR < 30 mL / min / 1.73 m) was excluded. 2 Patients with a history of cardiovascular disease, including cardiovascular risk factors, past and current cardiovascular events, and current medication regimens were also excluded. During interviews and from each individual's medical files, a medical history was obtained, including cardiovascular disease risk factors, past and current cardiovascular events, and current medication regimens. Weight, height, and waist circumference were measured, and body mass index (BMI) was calculated. After patients had been seated for at least 15 minutes, physicians measured brachial blood pressure with a mercury sphygmomanometer. The average of three measurements was used for analysis. [Example]

[0122] Blood and urine measurements Venous blood samples were collected from all patients after an 8-hour overnight fast. Immediately after collection, the blood samples were centrifuged at 3,000 rpm for 10 minutes, and the plasma samples were frozen at -70°C until analysis. Each standard and plasma sample was analyzed twice, and the average value was used for all subsequent analyses. Plasma high-sensitivity C-reactive protein (hs-CRP) levels were determined using a latex-enhanced immunoturbidimetric assay (Dade Behring, Marburg, Germany). Plasma N-terminal pro b-type natriuretic peptide (NT-proBNP) levels were determined by sandwich immunoassay (EIMA) using two antibodies (Cortez Diagnostics, Calabasas, CA, USA). Plasma ADMA levels were measured using an ADMA Fast ELISA kit (DLD Diagnostika, Hamburg, Germany). Nighttime urine samples were obtained for albumin excretion rate measurements. Normal albuminuria was defined as an albumin excretion rate of less than 20 mg / min, moderately elevated albuminuria (previously known as microalbuminuria) was defined as an albumin excretion rate of 20 to 200 mg / min, and severe albuminuria (previously known as macroalbuminuria) was defined as an albumin excretion rate of more than 200 mg / min. [Example]

[0123] Endothelial microparticle extraction and measurement of NOX5 CD144+ microparticles were isolated as described with modifications (Shang F, Wang SC, Hsu CY, Miao Y, Martin M, Yin Y, et al. MicroRNA-92a Mediates Endothelial Dysfunction in CKD. J Am Soc Nephrol. 2017;28(11):3251-61. Epub 2017 / 07 / 12. doi: 10.1681 / ASN.2016111215. PubMed PMID: 28696247; PubMed Central PMCID: PMCPMC5661278, Chen Z, Wen L, Martin M, Hsu CY, Fang L, Lin FM, et al. Oxidative stress activates endothelial innate immunity via sterol regulatory element binding protein 2 (SREBP2) transactivation of microRNA-92a. Circulation. 2015;131(9):805-14. Epub 2015 / 01 / 01. doi: 10.1161 / CIRCULATIONAHA.114.013675. PubMed PMID: 25550450; PubMed Central PMCID: PMCPMC4351177). Briefly, Dynabeads G (Invitrogen, Carlsbad, CA) were washed with PBS containing 0.1% BSA and then reconstituted in PBS. An anti-CD144 antibody (Santa Cruz Biotechnology, Dallas, TX), which specifically targets endothelial cells, was mixed with the washed Dynabeads G for 2 hours and then incubated with a 1:200 diluted plasma sample at 4°C overnight. After precipitation, Dynabeads G were washed three times with PBS and 1% Tween-20. The purity of CD144+ MPs was 70%±5.6% as determined by FACS analysis. The particle size was assessed using FITC-conjugated beads as a size reference and was less than 0.5 μm in diameter.Human NADPH oxidase 5 (NOX5) levels were measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit (Cusabio Technology, Houston, Texas) according to the manufacturer's instructions. Samples were stored at -70°C from the date of collection in 2008 until testing for NOX5 in 2014 (a total of 50 samples were available). The intra- and inter-assay coefficients of variation for the test were less than 8% and 10%, respectively. [Example]

[0124] animal Because mice do not naturally express the NOX5 gene, we generated and tested humanized NOX5 knock-in (KI) mice as previously described (Casas AI, Kleikers PW, Geuss E, Langhauser F, Adler T, Busch DH, et al. Calcium-dependent blood-brain barrier breakdown by NOX5 limits postreperfusion benefit in stroke. J Clin Invest. 2019;130:1772-8. Epub 2019 / 03 / 19. doi: 10.1172 / JCI124283. PubMed PMID: 30882367; PubMed Central PMCID: PMCPMC6436900). Mice were 129 / SV mice, specifically, 80% 129 / SV / 20% C57BI6 mice, as described (Casas AI, Kleikers PW, Geuss E, Langhauser F, Adler T, Busch DH, et al. Calcium-dependent blood-brain barrier breakdown by NOX5 limits postreperfusion benefit in stroke. J Clin Invest. 2019;130:1772-8. Epub 2019 / 03 / 19. doi: 10.1172 / JCI124283. PubMed PMID: 30882367; PubMed Central PMCID: PMCPMC6436900). Briefly, we developed a model using a hypoxanthine phosphoribosyltransferase (Hprt)-targeted transgenic approach under the control of the Tie2 promoter. Thus, our NOX5 KI mice express NOX5 in endothelial cells and leukocytes, which mimics the physiological expression of NOX5 in humans.The expression of NOX5 in KI mouse tissues has previously been verified by quantitative real-time PCR and compared with that in wild-type (WT) mice (Casas AI, Kleikers PW, Geuss E, Langhauser F, Adler T, Busch DH, et al. Calcium-dependent blood-brain barrier breakdown by NOX5 limits postreperfusion benefit in stroke. J Clin Invest. 2019;130:1772-8. Epub 2019 / 03 / 19. doi: 10.1172 / JCI124283. PubMed PMID: 30882367; PubMed Central PMCID: PMCPMC6436900). Age- and sex-matched groups of male and female mice (9–15 weeks old, n = 19–20 and 68–87 weeks old, n = 31–33) were used. All mice were kept in a temperature-controlled room (22°C) with free access to water and food and were kept on a 12-hour light-dark cycle. [Example]

[0125] Blood pressure recording (telemetry) NOX5 KI and WT mice were anesthetized with isoflurane (induction, 3–4%; maintenance, 1.5–2.5%) and underwent echocardiography (ultrasound) (Figure 13). Five days after ultrasound, mice were anesthetized using the same protocol and administered preoperative analgesia with subcutaneous injections of 0.05 mg / kg buprenorphine every 12 h. Each mouse was placed on a heating pad (UNO Temperature Control Unit, UNO Roestvaststaal), and body temperature was monitored using a rectal probe and maintained at 37.0°C using a feedback-controlled infrared light. An incision was made in the skin over the carotid artery. This incision created a pocket in the subcutaneous space in the flank for insertion of a telemetry transmitter (TA11PA-C10; Data Sciences, St. Paul, MN) to monitor blood pressure, heart rate, and locomotor activity. The left carotid artery was dissected, and three ligatures (5-0 silk) were placed at the bifurcation of the internal and external carotid arteries to occlude the vessel, at the heart to temporarily occlude the vessel, and midway between them to secure the catheter. The catheter was inserted through a small hole cut in the artery and advanced into the aortic arch. A pocket in the flank was then filled with 3 mL of prewarmed saline, and a transmitter was placed in the pocket. The wound was then closed using polysorbate 5-0 sutures. All surgical procedures were performed under aseptic conditions. Postoperative analgesia was provided by subcutaneous injection of 0.05 mg / kg buprenorphine after 6 hours and 5 mg / kg carprofen after 24 and 48 hours. Mice were allowed to recover for 7 to 14 days before measurements were initiated. Mice were housed individually in a quiet room.Blood pressure was measured over a 72-hour period at 10 cycles of 75 seconds per hour (Wang Y, Thorin E, Luo H, Tremblay J, Lavoie JL,Wu Z, et al. EPHB4 Protein Expression in Vascular Smooth Muscle Cells Regulates Their Contractility, and EPHB4 Deletion Leads to Hypotension in Mice. J Biol Chem. 2015;290(22):14235-44. Epub 2015 / 04 / 24. doi: 10.1074 / jbc.M114.621615. PubMed PMID: 25903126; PubMed Central PMCID: PMCPMC4447992, Xu P, Costa-Goncalves AC, Todiras M, Rabelo LA, Sampaio WO, Moura MM, et al. Endothelial dysfunction and elevated blood pressure in MAS gene-deleted mice. Hypertension. 2008;51(2):574-80. Epub 2008 / 01 / 09. doi: 10.1161 / HYPERTENSIONAHA. 107.102764. PubMed PMID: 18180400, Shirey-Rice JK, Klar R, Fentress HM, Redmon SN, Sabb TR, Krueger JJ, et al. Norepinephrine transporter variant A457P knock-in mice display key features of human postural orthostatic tachycardia syndrome. Dis Model Mech. 2013;6(4):1001-11. Epub 2013 / 04 / 13. doi: 10.1242 / dmm.012203. PubMed PMID: 23580201; PubMed Central PMCID: PMCPMC3701219).The radio signal from the transmitter was continuously monitored using a fully automated data acquisition system (Dataquest ART; Data Sciences). Mice were sacrificed by CO2 / O2 inhalation, and organs were removed for further analysis. Organ and body weight data are presented in Figure 6. [Example]

[0126] Myograph After mouse sacrifice, the thoracic aorta, femoral artery, and saphenous artery were dissected free of perivascular adipose tissue and mounted in a wire myograph (DMT, Aarhus, DK). The organ chamber was filled with Krebs-Ringer bicarbonate-buffered salt solution (KRB) continuously aerated with 95% O / 5% CO and maintained at 37°C. Passive stretch procedures were performed to mimic previously described physiologically relevant luminal diameters (Lazor R, Feihl F, Waeber B, Kucera P, Perret C. Endothelin-1 does not mediate the endothelium-dependent hypoxic contractions of small pulmonary arteries in rats. Chest. 1996;110(1):189–97. Epub 1996 / 07 / 01. doi: 10.1378 / chest.110.1.189. PubMed PMID: 8681627). Arterial contraction and relaxation responses were recorded at the luminal diameter corresponding to a distending pressure of 100 mmHg in the thoracic aorta and femoral artery, and at 90% of this diameter in the resistance-sized saphenous artery. This is justified by the lack of significant differences in diastolic arterial blood pressure between aged KI and WT mice. Given the comparable diameter-tension relationships, these diameters were not significantly different between the two mouse strains (Fig. 14). The diameter-tension relationship was constructed according to Laplace's law for cylindrical tubes: P = T / R (where P is the transmural pressure, T is the wall tension, and R is the lumen radius of the tube).Consequently, wall stiffness can equally be determined by recording 1) changes in tension in response to applied changes in radius (wire myography) or 2) changes in radius in response to changes in transmural pressure (pressure myography). (Bloksgaard M, Leurgans TM, Spronck B, Heusinkveld MHG, Thorsted B, Rosenstand K, et al. Imaging and modeling of acute pressure-induced changes of collagen and elastin microarchitectures in pig and human resistance arteries. Am J Physiol Heart Circ Physiol. 2017;313(1):H164-H78. Epub 2017 / 04 / 23. doi: 10.1152 / ajpheart.00110.2017. PubMed PMID: 28432057, Pourgeaud F, De Mey JG. Structural properties of rat mesenteric small arteries after 4-wk exposure to elevated or reduced blood flow. Am J Physiol. 1997;273(4):H1699-706. Epub 1997 / 11 / 15. doi: 10.1152 / ajpheart.1997.273.4.H1699. PubMed PMID: 9362233). Here, we used the former approach because it has higher throughput than the latter. Only the stress-strain relationship and better "incremental elastic (Young's) modulus" (which additionally requires recording of wall thickness) can help distinguish the contribution of structural from material properties to changes in arterial stiffness. Parts of isolated thoracic aorta were studied in the absence and partial continuous presence of 10 μM indomethacin, which inhibits the production of prostaglandins that can act as endothelium-derived vasoactive factors in this vessel. 40 mM K. +Vessels were tested for contractile responses to phenylephrine (0.01-100 μM) and endothelin-1 (1-256 nM) followed by acetylcholine (Ach) (0.01-100 μM), PAPA / NO (0.01-10 μM), or Bay60-2770 (0.01-10 μM)-induced relaxation. Wall tension of the vessel segments was continuously recorded using LabChart Pro (ADInstruments, Oxford, UK). [Example]

[0127] Measurement of superoxide formation: DHE labeling Superoxide was measured in the femoral artery using the fluorescent dye dihydroethidium (DHE) (Thermo Scientific Technology, The Netherlands). Frozen femoral artery cryosections were fixed with 4% paraformaldehyde (PFA) in PBS and then incubated with 2 μM DHE at 37°C for 30 min. After three PBS washing steps, the sections were incubated with 2 μg / ml DAPI (Sigma-Aldrich, The Netherlands) for 10 min. The sections were washed in PBS and then mounted using Dako Fluorescence Mounting Medium (S3023, Agilent Technologies). Immunofluorescence signals were visualized using a Leica DMI3000 B fluorescence microscope. Prior to DHE staining, some arteries were pretreated with 500 μM L-NAME for 30 min at 37°C. [Example]

[0128] RNA extraction, cDNA synthesis and quantitative real-time PCR The thoracic aorta, femoral artery, and saphenous artery were isolated from mice and immediately immersed in RNAlater solution (Thermo Fisher Scientific). RNA was extracted using the RNeasy® Micro Kit (Qiagen) according to the manufacturer's protocol. cDNA was synthesized from 1 μg of total RNA in a 20 μl reaction using the High Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific). After synthesis, the cDNA was stored at -20°C.

[0129] RT-qPCR was performed on a CFX96™ Real-Time PCR Detection System (Bio-Rad). All reactions were performed in triplicate in a total volume of 20 μl using TaqMan® Universal PCR Master Mix (Applied Biosystems-Life Technologies) according to the manufacturer's instructions. 3 μl of cDNA was used as a template, and predesigned TaqMan® primers for β-actin and Nox5 were used. Specific assay IDs for the primers used are listed in Supplementary Table 1. Standard PCR conditions were as follows: 95°C for 10 minutes, followed by 59 cycles of 95°C for 15 seconds and 60°C for 1 minute. The amount of mRNA was normalized to the measured expression of β-actin mRNA. [Example]

[0130] statistical analysis All human and animal data are expressed as mean ± SEM for numerical variables and numbers (percentages) for categorical variables. Comparisons of continuous variables between the two mouse groups were performed by Student's unpaired two-tailed t-test, and comparisons between the three human groups were performed by one-way analysis of variance (ANOVA) followed by Tukey's multiple comparison test (post-hoc test). Comparisons of categorical variables between human groups were performed using the χ 2Comparisons of telemetry data between two mouse groups were performed using two-way repeated measures ANOVA, and comparisons of myographs were performed using standard two-way ANOVA followed by Sidak's multiple comparison test. For subgroup analysis of NOX5 levels in human subjects, frequency analysis was performed, with bin widths calculated using Sturges' rule (Scott DW. Sturges' rule. Wire computational statistics. 2009;1(3):303-6. doi: https: / / doi.org / 10.1002 / wics.35). To assess the modality of the data, output frequencies were fitted to a single Gaussian and a sum of two Gaussian distributions, and a two-tailed F-test was performed with the Gaussian as the null hypothesis and the sum of two Gaussians as the alternative hypothesis. Furthermore, adjusted coefficients of determination values ​​were compared to select the best-fitting distribution for the sample. Given the bimodal nature of the samples, the area under each Gaussian distribution was calculated using the formula "amplitude * SD / 0.3989," and the proportion of NOX5 mechanotypes was then reported as the ratio between the two distributions. Data were analyzed using GraphPad Prism Version 8.2 (GraphPad Software, San Diego, CA). A p-value of less than 0.05 was considered to indicate statistical significance after correction for multiple testing.

[0131] (References) 1. Olsen MH, Angell SY, Asma S, Boutouyrie P, Burger D, Chirinos JA, et al. A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. Lancet. 2016;388(10060):2665-712. Epub 2016 / 09 / 28. doi: 10.1016 / S0140-6736(16)31134-5. PubMed PMID: 27671667. 2. Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, Cifkova R, Dominiczak AF, et al. Hypertension. Nat Rev Dis Primers. 2018;4:18014. Epub 2018 / 03 / 23. doi: 10.1038 / nrdp.2018.14. PubMed PMID: 29565029; PubMed Central PMCID: PMCPMC6477925. 3. Ogden LG, He J, Lydick E, Whelton PK. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension. 2000;35(2):539-43. Epub 2000 / 02 / 19. doi: 10.1161 / 01.hyp.35.2.539. PubMed PMID: 10679494. 4. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature. 1986;320(6061):454-6. Epub 1986 / 04 / 03. doi: 10.1038 / 320454a0. PubMed PMID: 3007998. 5. Kraja AT, Cook JP, Warren HR, Surendran P, Liu C, Evangelou E, et al. New Blood Pressure-Associated Loci Identified in Meta-Analyses of 475 000 Individuals. Circ Cardiovasc Genet. 2017;10(5). Epub 2017 / 10 / 17. doi: 10.1161 / CIRCGENETICS.117.001778. PubMed PMID: 29030403; PubMed Central PMCID: PMCPMC5776077. 6. Yogi A, Mercure C, Touyz J, Callera GE, Montezano AC, Aranha AB, et al. Renal redox-sensitive signaling, but not blood pressure, is attenuated by Nox1 knockout in angiotensin II-dependent chronic hypertension. Hypertension. 2008;51(2):500-6. Epub 2008 / 01 / 16. doi: 10.1161 / HYPERTENSIONAHA.107.103192. PubMed PMID: 18195161. 7. Murdoch CE, Alom-Ruiz SP, Wang M, Zhang M, Walker S, Yu B, et al. Role of endothelial Nox2 NADPH oxidase in angiotensin II-induced hypertension and vasomotor dysfunction. Basic Res Cardiol. 2011;106(4):527-38. Epub 2011 / 04 / 30. doi: 10.1007 / s00395-011-0179-7. PubMed PMID: 21528437; PubMed Central PMCID: PMCPMC3105229. 8. Sag CM, Schnelle M, Zhang J, Murdoch CE, Kossmann S, Protti A, et al. Distinct Regulatory Effects of Myeloid Cell and Endothelial Cell NAPDH Oxidase 2 on Blood Pressure. Circulation. 2017;135(22):2163-77. Epub 2017 / 03 / 17. doi: 10.1161 / CIRCULATIONAHA.116.023877. PubMed PMID: 28298457; PubMed Central PMCID: PMCPMC5444427. 9. Kleinschnitz C, Grund H, Wingler K, Armitage ME, Jones E, Mittal M, et al. Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS biology. 2010;8(9). Epub 2010 / 09 / 30. doi: 10.1371 / journal.pbio.1000479. PubMed PMID: 20877715. 10. Ray R, Murdoch CE, Wang M, Santos CX, Zhang M, Alom-Ruiz S, et al. Endothelial Nox4 NADPH oxidase enhances vasodilatation and reduces blood pressure in vivo. Arterioscler Thromb Vasc Biol. 2011;31(6):1368-76. Epub 2011 / 03 / 19. doi: 10.1161 / ATVBAHA.110.219238. PubMed PMID: 21415386. 11. Holterman CE, Thibodeau JF, Towaij C, Gutsol A, Montezano AC, Parks RJ, et al. Nephropathy and elevated BP in mice with podocyte-specific NADPH oxidase 5 expression. J Am Soc Nephrol. 2014;25(4):784-97. doi: 10.1681 / ASN.2013040371. PubMed PMID: 24262797; PubMed Central PMCID: PMCPMC3968494. 12. Jha JC, Banal C, Okabe J, Gray SP, Hettige T, Chow BSM, et al. NADPH Oxidase Nox5 Accelerates Renal Injury in Diabetic Nephropathy. Diabetes. 2017;66(10):2691-703. Epub 2017 / 07 / 28. doi: 10.2337 / db16-1585. PubMed PMID: 28747378. 13. Jha JC, Dai A, Holterman CE, Cooper ME, Touyz RM, Kennedy CR, et al. Endothelial or vascular smooth muscle cell-specific expression of human NOX5 exacerbates renal inflammation, fibrosis and albuminuria in the Akita mouse. Diabetologia. 2019;62(9):1712-26. Epub 2019 / 06 / 22. doi: 10.1007 / s00125-019-4924-z. PubMed PMID: 31222503. 14. Montezano AC, De Lucca Camargo L, Persson P, Rios FJ, Harvey AP, Anagnostopoulou A, et al. NADPH Oxidase 5 Is a Pro-Contractile Nox Isoform and a Point of Cross-Talk for Calcium and Redox Signaling-Implications in Vascular Function. J Am Heart Assoc. 2018;7(12). Epub 2018 / 06 / 17. doi: 10.1161 / JAHA.118.009388. PubMed PMID: 29907654; PubMed Central PMCID: PMCPMC6220544. 15. Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet. 2011;12(1):56-68. Epub 2010 / 12 / 18. doi: 10.1038 / nrg2918. PubMed PMID: 21164525; PubMed Central PMCID: PMCPMC3140052. 16. Alcaraz N, List M, Batra R, Vandin F, Ditzel HJ, Baumbach J. De novo pathway-based biomarker identification. Nucleic Acids Res. 2017;45(16):e151. Epub 2017 / 09 / 22. doi: 10.1093 / nar / gkx642. PubMed PMID: 28934488; PubMed Central PMCID: PMCPMC5766193. 17. Batra R, Alcaraz N, Gitzhofer K, Pauling J, Ditzel HJ, Hellmuth M, et al. On the performance of de novo pathway enrichment. NPJ Syst Biol Appl. 2017;3:6. Epub 2017 / 06 / 27. doi: 10.1038 / s41540-017-0007-2. PubMed PMID: 28649433; PubMed Central PMCID: PMCPMC5445589. 18. Menche J, Sharma A, Kitsak M, Ghiassian SD, Vidal M, Loscalzo J, et al. Disease networks. Uncovering disease-disease relationships through the incomplete interactome. Science. 2015;347(6224):1257601. Epub 2015 / 02 / 24. doi: 10.1126 / science.1257601. PubMed PMID: 25700523; PubMed Central PMCID: PMCPMC4435741. 19. Kotlyar M, Pastrello C, Malik Z, Jurisica I. IID 2018 update: context-specific physical protein-protein interactions in human, model organisms and domesticated species. Nucleic Acids Res. 2019;47(D1):D581-D9. Epub 2018 / 11 / 09. doi: 10.1093 / nar / gky1037. PubMed PMID: 30407591; PubMed Central PMCID: PMCPMC6323934. 20. Huttlin EL, Bruckner RJ, Paulo JA, Cannon JR, Ting L, Baltier K, et al. Architecture of the human interactome defines protein communities and disease networks. Nature. 2017;545(7655):505-9. Epub 2017 / 05 / 18. doi: 10.1038 / nature22366. PubMed PMID: 28514442; PubMed Central PMCID: PMCPMC5531611. 21. Choobdar S, Ahsen ME, Crawford J, Tomasoni M, Fang T, Lamparter D, et al. Assessment of network module identification across complex diseases. Nat Methods. 2019;16(9):843-52. Epub 2019 / 09 / 01. doi: 10.1038 / s41592-019-0509-5. PubMed PMID: 31471613; PubMed Central PMCID: PMCPMC6719725. 22. Arenas A, Fernandez A, Gomez S. Analysis of the structure of complex networks at different resolution levels. New Journal of Physics. 2008;10(5):053039. doi: 10.1088 / 1367-2630 / 10 / 5 / 053039. 23. Jiang P, Singh M. SPICi: a fast clustering algorithm for large biological networks. Bioinformatics. 2010;26(8):1105-11. Epub 2010 / 02 / 27. doi: 10.1093 / bioinformatics / btq078. PubMed PMID: 20185405; PubMed Central PMCID: PMCPMC2853685. 24. Dignat-George F, Boulanger CM. The many faces of endothelial microparticles. Arterioscler Thromb Vasc Biol. 2011;31(1):27-33. Epub 2010 / 12 / 17. doi: 10.1161 / ATVBAHA.110.218123. PubMed PMID: 21160065. 25. Aguirre-Plans J, Pinero J, Menche J, Sanz F, Furlong LI, Schmidt H, et al. Proximal Pathway Enrichment Analysis for Targeting Comorbid Diseases via Network Endopharmacology. Pharmaceuticals (Basel). 2018;11(3). Epub 2018 / 06 / 23. doi: 10.3390 / ph11030061. PubMed PMID: 29932108; PubMed Central PMCID: PMCPMC6160959. 26. Mazein A, Ostaszewski M, Kuperstein I, Watterson S, Le Novere N, Lefaudeux D, et al. Systems medicine disease maps: community-driven comprehensive representation of disease mechanisms. NPJ Syst Biol Appl. 2018;4:21. Epub 2018 / 06 / 07. doi: 10.1038 / s41540-018-0059-y. PubMed PMID: 29872544; PubMed Central PMCID: PMCPMC5984630. 27. Burns NS, Miller PW. Learning What We Didn't Know - The SPRINT Data Analysis Challenge. N Engl J Med. 2017;376(23):2205-7. Epub 2017 / 04 / 27. doi: 10.1056 / NEJMp1705323. PubMed PMID: 28445656. 28. Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation. 2006;113(13):1708-14. Epub 2006 / 04 / 06. doi: 10.1161 / CIRCULATIONAHA.105.602532. PubMed PMID: 16585403. 29. Perticone F, Sciacqua A, Maio R, Perticone M, Maas R, Boger RH, et al. Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential primary hypertension. J Am Coll Cardiol. 2005;46(3):518-23. Epub 2005 / 08 / 02. doi: 10.1016 / j.jacc.2005.04.040. PubMed PMID: 16053968. 30. Sonmez A, Celebi G, Erdem G, Tapan S, Genc H, Tasci I, et al. Plasma apelin and ADMA Levels in patients with essential primary hypertension. Clin Exp Hypertens. 2010;32(3):179-83. Epub 2010 / 05 / 28. doi: 10.3109 / 10641960903254505. PubMed PMID: 20504125. 31. Casas AI, Kleikers PW, Geuss E, Langhauser F, Adler T, Busch DH, et al. Calcium-dependent blood-brain barrier breakdown by NOX5 limits postreperfusion benefit in stroke. J Clin Invest. 2019;130:1772-8. Epub 2019 / 03 / 19. doi: 10.1172 / JCI124283. PubMed PMID: 30882367; PubMed Central PMCID: PMCPMC6436900. 32. Bubikat A, De Windt LJ, Zetsche B, Fabritz L, Sickler H, Eckardt D, et al. Local atrial natriuretic peptide signaling prevents hypertensive cardiac hypertrophy in endothelial nitric-oxide synthase-deficient mice. J Biol Chem. 2005;280(22):21594-9. Epub 2005 / 03 / 29. doi: 10.1074 / jbc.M501103200. PubMed PMID: 15793309. 33. Godecke A, Decking UK, Ding Z, Hirchenhain J, Bidmon HJ, Godecke S, et al. Coronary hemodynamics in endothelial NO synthase knockout mice. Circ Res. 1998;82(2):186-94. Epub 1998 / 02 / 19. doi: 10.1161 / 01.res.82.2.186. PubMed PMID: 9468189. 34. Devereux RB, Pickering TG, Alderman MH, Chien S, Borer JS, Laragh JH. Left ventricular hypertrophy in hypertension. Prevalence and relationship to pathophysiologic variables. Hypertension. 1987;9(2 Pt 2):1153-60. Epub 1987 / 02 / 01. doi: 10.1161 / 01.hyp.9.2_pt_2.ii53. PubMed PMID: 2879790. 35. Park JB, Schiffrin EL. Small artery remodeling is the most prevalent (earliest?) form of target organ damage in mild essential primary hypertension. J Hypertens. 2001;19(5):921-30. Epub 2001 / 06 / 08. doi: 10.1097 / 00004872-200105000-00013. PubMed PMID: 11393676. 36. Cuspidi C, Sala C, Negri F, Mancia G, Morganti A, Italian Society of H. Prevalence of left-ventricular hypertrophy in hypertension: an updated review of echocardiographic studies. J Hum Hypertens. 2012;26(6):343-9. Epub 2011 / 11 / 25. doi: 10.1038 / jhh.2011.104. PubMed PMID: 22113443. 37. Bezie Y, Lamaziere JM, Laurent S, Challande P, Cunha RS, Bonnet J, et al. Fibronectin expression and aortic wall elastic modulus in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol. 1998;18(7):1027-34. Epub 1998 / 07 / 22. doi: 10.1161 / 01.atv.18.7.1027. PubMed PMID: 9672062. 38. Hayoz D, Rutschmann B, Perret F, Niederberger M, Tardy Y, Mooser V, et al. Conduit artery compliance and distensibility are not necessarily reduced in hypertension. Hypertension. 1992;20(1):1-6. Epub 1992 / 07 / 01. doi: 10.1161 / 01.hyp.20.1.1. PubMed PMID: 1618544. 39. Lacolley P, Ghodsi N, Glazer E, Challande P, Brissac AM, Safar ME, et al. Influence of graded changes in vasomotor tone on the carotid arterial mechanics in live spontaneously hypertensive rats. Br J Pharmacol. 1995;115(7):1235-44. Epub 1995 / 08 / 01. doi: 10.1111 / j.1476-5381.1995.tb15031.x. PubMed PMID: 7582551; PubMed Central PMCID: PMCPMC1908801. 40. Intengan HD, Schiffrin EL. Structure and mechanical properties of resistance arteries in hypertension: role of adhesion molecules and extracellular matrix determinants. Hypertension. 2000;36(3):312-8. Epub 2000 / 09 / 16. doi: 10.1161 / 01.hyp.36.3.312. PubMed PMID: 10988257. 41. Bussy C, Boutouyrie P, Lacolley P, Challande P, Laurent S. Intrinsic stiffness of the carotid arterial wall material in essential hypertensives. Hypertension. 2000;35(5):1049-54. Epub 2000 / 05 / 20. doi: 10.1161 / 01.hyp.35.5.1049. PubMed PMID: 10818063. 42. Laurent S, Girerd X, Mourad JJ, Lacolley P, Beck L, Boutouyrie P, et al. Elastic modulus of the radial artery wall material is not increased in patients with essential primary hypertension. Arterioscler Thromb. 1994;14(7):1223-31. Epub 1994 / 07 / 01. doi: 10.1161 / 01.atv.14.7.1223. PubMed PMID: 8018679. 43. Laurent S, Hayoz D, Trazzi S, Boutouyrie P, Waeber B, Omboni S, et al. Isobaric compliance of the radial artery is increased in patients with essential primary hypertension. J Hypertens. 1993;11(1):89-98. Epub 1993 / 01 / 01. doi: 10.1097 / 00004872-199301000-00013. PubMed PMID: 8382244. 44. Laurent S. Arterial wall hypertrophy and stiffness in essential hypertensive patients. Hypertension. 1995;26(2):355-62. Epub 1995 / 08 / 01. doi: 10.1161 / 01.hyp.26.2.355. PubMed PMID: 7635546. 45. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288(5789):373-6. Epub 1980 / 11 / 27. doi: 10.1038 / 288373a0. PubMed PMID: 6253831. 46. Chennupati R, Lamers WH, Koehler SE, De Mey JG. Endotheliumdependent hyperpolarization-related relaxations diminish with age in murine saphenous arteries of both sexes. Br J Pharmacol. 2013;169(7):1486-99. Epub 2013 / 03 / 16. doi: 10.1111 / bph.12175. PubMed PMID: 23488619; PubMed Central PMCID: PMCPMC3724106. 47. Chennupati R, Meens MJ, Marion V, Janssen BJ, Lamers WH, De Mey JG, et al. Endothelial arginine resynthesis contributes to the maintenance of vasomotor function in male diabetic mice. PLoS One. 2014;9(7):e102264. Epub 2014 / 07 / 18. doi: 10.1371 / journal.pone.0102264. PubMed PMID: 25033204; PubMed Central PMCID: PMCPMC4102520. 48. Chennupati R, Meens MJ, Janssen BJ, van Dijk P, Hakvoort TBM, Lamers WH, et al. Deletion of endothelial arginase 1 does not improve vasomotor function in diabetic mice. Physiol Rep. 2018;6(11):e13717. Epub 2018 / 06 / 12. doi: 10.14814 / phy2.13717. PubMed PMID: 29890043; PubMed Central PMCID: PMCPMC5995309. 49. Ryan MJ, Didion SP, Davis DR, Faraci FM, Sigmund CD. Endothelial dysfunction and blood pressure variability in selected inbred mouse strains. Arterioscler Thromb Vasc Biol. 2002;22(1):42-8. Epub 2002 / 01 / 15. doi: 10.1161 / hq0102.101098. PubMed PMID: 11788459. 50. Gebhart V, Reiss K, Kollau A, Mayer B, Gorren ACF. Site and mechanism of uncoupling of nitric-oxide synthase: Uncoupling by monomerization and other misconceptions. Nitric Oxide. 2019;89:14-21. Epub 2019 / 04 / 26. doi: 10.1016 / j.niox.2019.04.007. PubMed PMID: 31022534. 51. Mendes-Silverio CB, Leiria LO, Morganti RP, Anhe GF, Marcondes S, Monica FZ, et al. Activation of haem-oxidized soluble guanylyl cyclase with BAY 60-2770 in human platelets lead to overstimulation of the cyclic GMP signaling pathway. PLoS One. 2012;7(11):e47223. Epub 2012 / 11 / 13. doi: 10.1371 / journal.pone.0047223. PubMed PMID: 23144808; PubMed Central PMCID: PMCPMC3493568. 52. Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, H SA, Meurer S, et al. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest. 2006;116(9):2552-61. Epub 2006 / 09 / 07. doi: 10.1172 / JCI28371. PubMed PMID: 16955146; PubMed Central PMCID: PMCPMC1555649. 53. Hrabie JA, Klose JR, Wink DA, Keefer LK. New nitric oxide-releasing zwitterions derived from polyamines. The Journal of Organic Chemistry. 1993;58(6):1472-6. doi: 10.1021 / jo00058a030. 54. Kietadisorn R, Juni RP, Moens AL. Tackling endothelial dysfunction by modulating NOS uncoupling: new insights into its pathogenesis and therapeutic possibilities. Am J Physiol Endocrinol Metab. 2012;302(5):E481-95. Epub 2011 / 12 / 15. doi: 10.1152 / ajpendo.00540.2011. PubMed PMID: 22167522. 55. Altenhofer S, Kleikers PW, Radermacher KA, Scheurer P, Rob Hermans JJ, Schiffers P, et al. The NOX toolbox: validating the role of NADPH oxidases in physiology and disease. Cell Mol Life Sci. 2012;69(14):2327-43. Epub 2012 / 06 / 01. doi: 10.1007 / s00018-012-1010-9. PubMed PMID: 22648375; PubMed Central PMCID: PMCPMC3383958. 56. Altenhofer S, Radermacher KA, Kleikers PW, Wingler K, Schmidt HH. Evolution of NADPH Oxidase Inhibitors: Selectivity and Mechanisms for Target Engagement. Antioxid Redox Signal. 2015;23(5):406-27. doi: 10.1089 / ars.2013.5814. PubMed PMID: 24383718; PubMed Central PMCID: PMCPMC4543484. 57. Augsburger F, Filippova A, Rasti D, Seredenina T, Lam M, Maghzal G, et al. Pharmacological characterization of the seven human NOX isoforms and their inhibitors. Redox Biol. 2019;26:101272. Epub 2019 / 07 / 23. doi: 10.1016 / j.redox.2019.101272. PubMed PMID: 31330481; PubMed Central PMCID: PMCPMC6658998. 58. Dao VT, Elbatreek MH, Altenhofer S, Casas AI, Pachado MP, Neullens CT, et al. Isoform-selective NADPH oxidase inhibitor panel for pharmacological target validation. Free Radic Biol Med. 2019. Epub 2019 / 12 / 29. doi: 10.1016 / j.freeradbiomed.2019.12.038. PubMed PMID: 31883469. 59. Frangos S, Buscombe JR. Why should we be concerned about a “g”? European Journal of Nuclear Medicine and Molecular Imaging. 2019;46(2):519-. doi: 10.1007 / s00259-018-4204-z. 60. Hornsten C, Weidung B, Littbrand H, Carlberg B, Nordstrom P, Lovheim H, et al. High blood pressure as a risk factor for incident stroke among very old people: a population-based cohort study. J Hypertens. 2016;34(10):2059-65. Epub 2016 / 07 / 20. doi: 10.1097 / HJH.0000000000001048. PubMed PMID: 27434102; PubMed Central PMCID: PMCPMC5398900. 61. Guzik TJ, Chen W, Gongora MC, Guzik B, Lob HE, Mangalat D, et al. Calcium-dependent NOX5 nicotinamide adenine dinucleotide phosphate oxidase contributes to vascular oxidative stress in human coronary artery disease. J Am Coll Cardiol. 2008;52(22):1803-9. Epub 2008 / 11 / 22. doi: 10.1016 / j.jacc.2008.07.063. PubMed PMID: 19022160; PubMed Central PMCID: PMCPMC2593790. 62. Li H, Han X, Hu Z, Huang J, Chen J, Hixson JE, et al. Associations of NADPH oxidase-related genes with blood pressure changes and incident hypertension: The GenSalt Study. J Hum Hypertens. 2018;32(4):287-93. Epub 2018 / 02 / 22. doi: 10.1038 / s41371-018-0041-6. PubMed PMID: 29463833; PubMed Central PMCID: PMCPMC5889722. 63. Elbatreek MH, Pachado MP, Cuadrado A, Jandeleit-Dahm K, Schmidt H. Reactive Oxygen Comes of Age: Mechanism-Based Therapy of Diabetic End-Organ Damage. Trends Endocrinol Metab. 2019. Epub 2019 / 04 / 01. doi: 10.1016 / j.tem.2019.02.006. PubMed PMID: 30928357. 64. Hermann M, Flammer A, Luscher TF. Nitric oxide in hypertension. J Clin Hypertens (Greenwich). 2006;8(12 Suppl 4):17-29. Epub 2006 / 12 / 16. doi: 10.1111 / j.1524-6175.2006.06032.x. PubMed PMID: 17170603. 65. Helbing T, Olivier C, Bode C, Moser M, Diehl P. Role of microparticles in endothelial dysfunction and arterial hypertension. World J Cardiol. 2014;6(11):1135-9. Epub 2014 / 11 / 28. doi: 10.4330 / wjc.v6.i11.1135. PubMed PMID: 25429325; PubMed Central PMCID: PMCPMC4244610. 66. Shantsila E. Endothelial microparticles: a universal marker of vascular health? J Hum Hypertens. 2009;23(5):359-61. Epub 2008 / 11 / 21. doi: 10.1038 / jhh.2008.138. PubMed PMID: 19020535. 67. Burger D, Turner M, Munkonda MN, Touyz RM. Endothelial Microparticle-Derived Reactive Oxygen Species: Role in Endothelial Signaling and Vascular Function. Oxid Med Cell Longev. 2016;2016:5047954. Epub 2016 / 06 / 18. doi: 10.1155 / 2016 / 5047954. PubMed PMID: 27313830; PubMed Central PMCID: PMCPMC4893592. 68. Montezano AC, Burger D, Paravicini TM, Chignalia AZ, Yusuf H, Almasri M, et al. Nicotinamide adenine dinucleotide phosphate reduced oxidase 5 (Nox5) regulation by angiotensin II and endothelin-1 is mediated via calcium / calmodulin-dependent, rac-1-independent pathways in human endothelial cells. Circ Res. 2010;106(8):1363-73. Epub 2010 / 03 / 27. doi: 10.1161 / CIRCRESAHA.109.216036. PubMed PMID: 20339118; PubMed Central PMCID: PMCPMC3119893. 69. Yu P, Han W, Villar VA, Yang Y, Lu Q, Lee H, et al. Unique role of NADPH oxidase 5 in oxidative stress in human renal proximal tubule cells. Redox Biol. 2014;2:570-9. Epub 2014 / 04 / 02. doi: 10.1016 / j.redox.2014.01.020. PubMed PMID: 24688893; PubMed Central PMCID: PMCPMC3969603. 70. Hahn NE, Meischl C, Kawahara T, Musters RJ, Verhoef VM, van der Velden J, et al. NOX5 expression is increased in intramyocardial blood vessels and cardiomyocytes after acute myocardial infarction in humans. Am J Pathol. 2012;180(6):2222-9. Epub 2012 / 04 / 17. doi: 10.1016 / j.ajpath.2012.02.018. PubMed PMID: 22503554. 71. Holterman CE, Thibodeau JF, Kennedy CR. NADPH oxidase 5 and renal disease. Curr Opin Nephrol Hypertens. 2015;24(1):81-7. Epub 2014 / 11 / 22. doi: 10.1097 / MNH.0000000000000081. PubMed PMID: 25415612. 72. Bouabout G, Ayme-Dietrich E, Jacob H, Champy MF, Birling MC, Pavlovic G, et al. Nox4 genetic inhibition in experimental hypertension and metabolic syndrome. Arch Cardiovasc Dis. 2018;111(1):41-52. Epub 2017 / 11 / 09. doi: 10.1016 / j.acvd.2017.03.011. PubMed PMID: 29113787. 73. Schroder K, Zhang M, Benkhoff S, Mieth A, Pliquett R, Kosowski J, et al. Nox4 is a protective reactive oxygen species generating vascular NADPH oxidase. Circ Res. 2012;110(9):1217-25. Epub 2012 / 03 / 30. doi: 10.1161 / CIRCRESAHA.112.267054. PubMed PMID: 22456182. 74. Veith C, Kraut S, Wilhelm J, Sommer N, Quanz K, Seeger W, et al. NADPH oxidase 4 is not involved in hypoxia-induced pulmonary hypertension. Pulm Circ. 2016;6(3):397-400. Epub 2016 / 09 / 30. doi: 10.1086 / 687756. PubMed PMID: 27683617; PubMed Central PMCID: PMCPMC5019094. 75. Brandes RP, Takac I, Schroder K. No superoxide--no stress?: Nox4, the good NADPH oxidase! Arterioscler Thromb Vasc Biol. 2011;31(6):1255-7. Epub 2011 / 05 / 20. doi: 10.1161 / ATVBAHA.111.226894. PubMed PMID: 21593458. 76. Miura H, Bosnjak JJ, Ning G, Saito T, Miura M, Gutterman DD. Role for hydrogen peroxide in flow-induced dilation of human coronary arterioles. Circ Res. 2003;92(2):e31-40. Epub 2003 / 02 / 08. doi: 10.1161 / 01.res.0000054200.44505.ab. PubMed PMID: 12574154. 77. Leurgans TM, Bloksgaard M, Brewer JR, Bagatolli LA, Fredgart MH, Rosenstand K, et al. Endothelin-1 shifts the mediator of bradykinin-induced relaxation from NO to H2O2in resistance arteries from patients with cardiovascular disease. Br J Pharmacol. 2016;173(10):1653-64. Epub 2016 / 02 / 26. doi: 10.1111 / bph.13467. PubMed PMID: 26914408; PubMed Central PMCID: PMCPMC4842913. 78. Shimokawa H. Hydrogen peroxide as an endothelium-derived hyperpolarizing factor. Pflugers Arch. 2010;459(6):915-22. Epub 2010 / 02 / 09. doi: 10.1007 / s00424-010-0790-8. PubMed PMID: 20140449. 79. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest. 2003;111(8):1201-9. Epub 2003 / 04 / 17. doi: 10.1172 / JCI14172. PubMed PMID: 12697739; PubMed Central PMCID: PMCPMC152929. 80. Dumitrescu C, Biondi R, Xia Y, Cardounel AJ, Druhan LJ, Ambrosio G, et al. Myocardial ischemia results in tetrahydrobiopterin (BH4) oxidation with impaired endothelial function ameliorated by BH4. Proc Natl Acad Sci U S A. 2007;104(38):15081-6. Epub 2007 / 09 / 13. doi: 10.1073 / pnas.0702986104. PubMed PMID: 17848522; PubMed Central PMCID: PMCPMC1986616. 81. Mitchell BM, Dorrance AM, Webb RC. GTP cyclohydrolase 1 inhibition attenuates vasodilation and increases blood pressure in rats. Am J Physiol Heart Circ Physiol. 2003;285(5):H2165-70. Epub 2003 / 07 / 12. doi: 10.1152 / ajpheart.00253.2003. PubMed PMID: 12855421. 82. Pi X, Xie L, Portbury AL, Kumar S, Lockyer P, Li X, et al. NADPH oxidase-generated reactive oxygen species are required for stromal cell-derived factor-1alphastimulated angiogenesis. Arterioscler Thromb Vasc Biol. 2014;34(9):2023-32. Epub 2014 / 07 / 06. doi: 10.1161 / ATVBAHA.114.303733. PubMed PMID: 24990230; PubMed Central PMCID: PMCPMC4149803. 83. Barton M, Cosentino F, Brandes RP, Moreau P, Shaw S, Luscher TF. Anatomic heterogeneity of vascular aging: role of nitric oxide and endothelin. Hypertension. 1997;30(4):817-24. Epub 1997 / 10 / 23. doi: 10.1161 / 01.hyp.30.4.817. PubMed PMID: 9336378. 84. Matz RL, de Sotomayor MA, Schott C, Stoclet JC, Andriantsitohaina R. Vascular bed heterogeneity in age-related endothelial dysfunction with respect to NO and eicosanoids. Br J Pharmacol. 2000;131(2):303-11. Epub 2000 / 09 / 19. doi: 10.1038 / sj.bjp.0703568. PubMed PMID: 10991924; PubMed Central PMCID: PMCPMC1572322. 85. Wang S, Xu J, Song P, Wu Y, Zhang J, Chul Choi H, et al. Acute inhibition of guanosine triphosphate cyclohydrolase 1 uncouples endothelial nitric oxide synthase and elevates blood pressure. Hypertension. 2008;52(3):484-90. Epub 2008 / 07 / 23. doi: 10.1161 / HYPERTENSIONAHA.108.112094. PubMed PMID: 18645049; PubMed Central PMCID: PMCPMC3523107. 86. Podjarny E, Hasdan G, Bernheim J, Rashid G, Green J, Korzets Z, et al. Effect of chronic tetrahydrobiopterin supplementation on blood pressure and proteinuria in 5 / 6 nephrectomized rats. Nephrol Dial Transplant. 2004;19(9):2223-7. Epub 2004 / 07 / 15. doi: 10.1093 / ndt / gfh383. PubMed PMID: 15252157. 87. Sundberg JP, Berndt A, Sundberg BA, Silva KA, Kennedy V, Bronson R, et al. The mouse as a model for understanding chronic diseases of aging: the histopathologic basis of aging in inbred mice. Pathobiol Aging Age Relat Dis. 2011;1. Epub 2011 / 01 / 01. doi: 10.3402 / pba.v1i0.7179. PubMed PMID: 22953031; PubMed Central PMCID: PMCPMC3417678. 88. Porkert M, Sher S, Reddy U, Cheema F, Niessner C, Kolm P, et al. Tetrahydrobiopterin: a novel antihypertensive therapy. J Hum Hypertens. 2008;22(6):401-7. Epub 2008 / 03 / 07. doi: 10.1038 / sj.jhh.1002329. PubMed PMID: 18322548. 89. McRae MP. High-dose folic acid supplementation effects on endothelial function and blood pressure in hypertensive patients: a meta-analysis of randomized controlled clinical trials. J Chiropr Med. 2009;8(1):15-24. Epub 2009 / 08 / 04. doi: 10.1016 / j.jcm.2008.09.001. PubMed PMID: 19646382; PubMed Central PMCID: PMCPMC2697578. 90. Kong X, Huang X, Zhao M, Xu B, Xu R, Song Y, et al. Platelet Count Affects Efficacy of Folic Acid in Preventing First Stroke. J Am Coll Cardiol. 2018;71(19):2136-46. Epub 2018 / 05 / 12. doi: 10.1016 / j.jacc.2018.02.072. PubMed PMID: 29747834. 91. Huo Y, Li J, Qin X, Huang Y, Wang X, Gottesman RF, et al. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. JAMA. 2015;313(13):1325-35. Epub 2015 / 03 / 17. doi: 10.1001 / jama.2015.2274. PubMed PMID: 25771069. 92. Wang WW, Wang XS, Zhang ZR, He JC, Xie CL. A Meta-Analysis of Folic Acid in Combination with Anti-Hypertension Drugs in Patients with Hypertension and Hyperhomocysteinemia. Front Pharmacol. 2017;8:585. Epub 2017 / 09 / 16. doi: 10.3389 / fphar.2017.00585. PubMed PMID: 28912716; PubMed Central PMCID: PMCPMC5584015. 93. Hsu CY, Huang PH, Chiang CH, Leu HB, Huang CC, Chen JW, et al. Increased circulating endothelial apoptotic microparticle to endothelial progenitor cell ratio is associated with subsequent decline in glomerular filtration rate in hypertensive patients. PLoS One. 2013;8(7):e68644. Epub 2013 / 07 / 23. doi: 10.1371 / journal.pone.0068644. PubMed PMID: 23874701; PubMed Central PMCID: PMCPMC3709900. 94. Huang PH, Huang SS, Chen YH, Lin CP, Chiang KH, Chen JS, et al. Increased circulating CD31+ / annexin V+ apoptotic microparticles and decreased circulating endothelial progenitor cell levels in hypertensive patients with microalbuminuria. J Hypertens. 2010;28(8):1655-65. Epub 2010 / 06 / 04. doi: 10.1097 / HJH.0b013e32833a4d0a. PubMed PMID: 20520578. 95. Shang F, Wang SC, Hsu CY, Miao Y, Martin M, Yin Y, et al. MicroRNA-92a Mediates Endothelial Dysfunction in CKD. J Am Soc Nephrol. 2017;28(11):3251-61. Epub 2017 / 07 / 12. doi: 10.1681 / ASN.2016111215. PubMed PMID: 28696247; PubMed Central PMCID: PMCPMC5661278. 96. Chen Z, Wen L, Martin M, Hsu CY, Fang L, Lin FM, et al. Oxidative stress activates endothelial innate immunity via sterol regulatory element binding protein 2 (SREBP2) transactivation of microRNA-92a. Circulation. 2015;131(9):805-14. Epub 2015 / 01 / 01. doi: 10.1161 / CIRCULATIONAHA.114.013675. PubMed PMID: 25550450; PubMed Central PMCID: PMCPMC4351177. 97. Wang Y, Thorin E, Luo H, Tremblay J, Lavoie JL,Wu Z, et al. EPHB4 Protein Expression in Vascular Smooth Muscle Cells Regulates Their Contractility, and EPHB4 Deletion Leads to Hypotension in Mice. J Biol Chem. 2015;290(22):14235-44. Epub 2015 / 04 / 24. doi: 10.1074 / jbc.M114.621615. PubMed PMID: 25903126; PubMed Central PMCID: PMCPMC4447992. 98. Xu P, Costa-Goncalves AC, Todiras M, Rabelo LA, Sampaio WO, Moura MM, et al. Endothelial dysfunction and elevated blood pressure in MAS gene-deleted mice. Hypertension. 2008;51(2):574-80. Epub 2008 / 01 / 09. doi: 10.1161 / HYPERTENSIONAHA. 107.102764. PubMed PMID: 18180400. 99. Shirey-Rice JK, Klar R, Fentress HM, Redmon SN, Sabb TR, Krueger JJ, et al. Norepinephrine transporter variant A457P knock-in mice display key features of human postural orthostatic tachycardia syndrome. Dis Model Mech. 2013;6(4):1001-11. Epub 2013 / 04 / 13. doi: 10.1242 / dmm.012203. PubMed PMID: 23580201; PubMed Central PMCID: PMCPMC3701219. 100. Lazor R, Feihl F, Waeber B, Kucera P, Perret C. Endothelin-1 does not mediate the endothelium-dependent hypoxic contractions of small pulmonary arteries in rats. Chest. 1996;110(1):189-97. Epub 1996 / 07 / 01. doi: 10.1378 / chest.110.1.189. PubMed PMID: 8681627. 101. Bloksgaard M, Leurgans TM, Spronck B, Heusinkveld MHG, Thorsted B, Rosenstand K, et al. Imaging and modeling of acute pressure-induced changes of collagen and elastin microarchitectures in pig and human resistance arteries. Am J Physiol Heart Circ Physiol. 2017;313(1):H164-H78. Epub 2017 / 04 / 23. doi: 10.1152 / ajpheart.00110.2017. PubMed PMID: 28432057. 102. Pourageaud F, De Mey JG. Structural properties of rat mesenteric small arteries after 4-wk exposure to elevated or reduced blood flow. Am J Physiol. 1997;273(4):H1699-706. Epub 1997 / 11 / 15. doi: 10.1152 / ajpheart.1997.273.4.H1699. PubMed PMID: 9362233. 103. Scott DW. Sturges' rule. Wire computational statistics. 2009;1(3):303-6. doi: https: / / doi.org / 10.1002 / wics.35.

Claims

1. 1. A method for aiding in the diagnosis of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 5 (NOX5, NAPDH oxidase 5)-dependent hypertension in a subject suffering from essential arterial hypertension, comprising: (a) isolating endothelial microparticles from a plasma sample; and (b) measuring NOX5 in said endothelial microparticles of step (a) using a protein detection assay and determining the concentration of NOX5 in said plasma sample as pg of NOX5 per ml of plasma sample. The method comprises determining the level of NOX5 in a plasma sample from the subject by: ...

2. A therapeutic agent for a subject with essential arterial hypertension, comprising a compound selected from sepiapterin, folic acid, and tetrahydrobiopterin, wherein the subject is a subject shown to be suffering from NOX5-dependent hypertension by the method of claim 1.

3. A therapeutic agent for a subject with essential arterial hypertension, comprising a compound selected from L-citrulline and L-arginine, wherein the subject is a subject who has been shown to suffer from NOX5-dependent hypertension by the method of claim 1.

4. A therapeutic agent for a subject with essential arterial hypertension, comprising a NOX5 inhibitor, wherein the subject is a subject shown to be suffering from NOX5-dependent hypertension by the method of claim 1.

5. The therapeutic agent according to any one of claims 2 to 4, wherein the essential arterial hypertension is NOX5-dependent hypertension.

6. The therapeutic agent according to any one of claims 2 to 4, wherein the subject has treatment-resistant hypertension.

7. A therapeutic agent for a subject with NOX5-dependent hypertension, comprising a compound selected from sepiapterin, folic acid, and tetrahydrobiopterin, wherein the subject is a subject shown to be suffering from NOX5-dependent hypertension by the method of claim 1.

8. A therapeutic agent for a subject with NOX5-dependent hypertension, comprising a compound selected from L-citrulline and L-arginine, wherein the subject is a subject who has been shown to be suffering from NOX5-dependent hypertension by the method of claim 1.

9. A therapeutic agent for a subject with NOX5-dependent hypertension, comprising a NOX5 inhibitor, wherein the subject is a subject shown to be suffering from NOX5-dependent hypertension by the method of claim 1.

10. The therapeutic agent according to claim 2 or 7, which is sepiapterin.

11. The method of any one of claims 2 to 10, wherein the subject has moderately elevated albuminuria, defined as an albumin excretion rate of 20 to 200 mg per minute.

12. The method of any one of claims 2 to 11, wherein the subject is at least 53 years old.

13. The method of any one of claims 2 to 12, wherein the subject is at least 57 years old.

14. The therapeutic agent according to any one of claims 2 to 13, wherein the subject has a plasma concentration of asymmetric dimethylarginine that is higher than the average plasma concentration of asymmetric dimethylarginine in a group of healthy subjects.

15. The method of any one of claims 2 to 14, wherein the subject has a plasma concentration of asymmetric dimethylarginine of at least 0.53 micromoles per liter.

16. 10. The method of claim 1, wherein the subject has hypertension defined as a systolic blood pressure of at least 140 mmHg, a diastolic blood pressure of at least 90 mmHg, or the use of antihypertensive medication.

17. 17. The method of claim 1 or 16, wherein the subject does not have a history or clinical evidence of any of the following: angina, myocardial infarction, congestive heart failure, peripheral vascular disease, inflammatory disease, and any disease that predisposes to vasculitis, and the subject does not have stage 4 or stage 5 chronic kidney disease.

18. A therapeutic agent for a subject having essential arterial hypertension or NOX5-dependent hypertension, comprising a compound selected from sepiapterin, folic acid, tetrahydrobiopterin, L-citrulline, L-arginine, and a NOX5 inhibitor, wherein the subject is a subject who has been shown to be suffering from NOX5-dependent hypertension by the method of claim 1.

19. Use of a compound selected from sepiapterin, folic acid, tetrahydrobiopterin, L-citrulline, L-arginine, and a NOX5 inhibitor in the manufacture of a medicament for treating a subject with essential arterial hypertension or NOX5-dependent hypertension, wherein the subject is a subject shown to be suffering from NOX5-dependent hypertension by the method of claim 1.

20. The therapeutic agent according to claim 4 or 9, wherein the NOX5 inhibitor is 5,12-dihydroquinoxalino(2,3-b)quinoxaline (ML090).

21. The therapeutic agent of claim 15, wherein the subject has a plasma concentration of asymmetric dimethylarginine of at least 0.58 micromoles per liter.

22. The therapeutic agent of claim 21, wherein the subject has a plasma concentration of asymmetric dimethylarginine of at least 0.63 micromoles per liter.

23. A therapeutic agent described in any of claims 2 to 15, wherein the subject is suffering from hypertension defined as a systolic blood pressure of at least 140 mmHg, hypertension defined as a diastolic blood pressure of at least 90 mmHg, or hypertension defined as the use of antihypertensive medication.

24. A therapeutic agent described in any of claims 2 to 15 and 23, wherein the subject does not have a history or clinical evidence of any of the following diseases: angina, myocardial infarction, congestive heart failure, peripheral vascular disease, inflammatory disease, and any disease that predisposes to vasculitis, and the subject does not have stage 4 or stage 5 chronic kidney disease.

Images